<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Uterine Fibroids — OB-GYN Medical Lecture</title>
  <meta name="description"
    content="Uterine Fibroids (Leiomyomas) — Interactive Medical School Lecture covering epidemiology, pathophysiology, FIGO classification, diagnosis, and management.">
  <meta property="og:title" content="Uterine Fibroids — OB-GYN Interactive Medical Lecture">
  <meta property="og:description"
    content="Next-generation interactive medical lecture on Uterine Leiomyomas for medical students and educators.">
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link
    href="https://fonts.googleapis.com/css2?family=DM+Serif+Display:ital@0;1&family=DM+Sans:wght@300;400;500;600&family=DM+Mono:wght@400;500&display=swap"
    rel="stylesheet">
  <script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.12.2/gsap.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.12.2/ScrollTrigger.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.12.2/ScrollToPlugin.min.js"></script>
  <style>
    /* ============================================================
   DESIGN SYSTEM — UTERINE FIBROIDS MEDICAL LECTURE
   Cinematic Dark Medical × Anatomical Precision
   ============================================================ */

    :root {
      --bg: #060810;
      --bg-1: #0d0f1a;
      --bg-2: #131629;
      --bg-card: #0f1120;
      --bg-card-2: #161929;

      --purple: #b57bee;
      --purple-dim: #7c3aed;
      --purple-glow: rgba(181, 123, 238, 0.15);
      --pink: #f06292;
      --pink-glow: rgba(240, 98, 146, 0.12);
      --teal: #4dd0e1;
      --teal-glow: rgba(77, 208, 225, 0.1);
      --amber: #ffb74d;
      --red: #ef5350;
      --green: #66bb6a;

      --text-1: #f0f0ff;
      --text-2: #c0c2e0;
      --text-3: #6e71a0;

      --border: rgba(181, 123, 238, 0.12);
      --border-2: rgba(255, 255, 255, 0.06);

      --font-display: 'DM Serif Display', Georgia, serif;
      --font-body: 'DM Sans', system-ui, sans-serif;
      --font-mono: 'DM Mono', 'Courier New', monospace;

      --radius: 16px;
      --radius-sm: 8px;
      --radius-lg: 24px;

      --shadow-card: 0 4px 40px rgba(0, 0, 0, 0.5), 0 0 60px rgba(181, 123, 238, 0.04);
      --shadow-glow: 0 0 80px rgba(181, 123, 238, 0.2);
      --transition: 0.4s cubic-bezier(0.16, 1, 0.3, 1);
    }

    *,
    *::before,
    *::after {
      box-sizing: border-box;
      margin: 0;
      padding: 0;
    }

    html {
      scroll-behavior: smooth;
      font-size: 16px;
    }

    body {
      background: var(--bg);
      color: var(--text-1);
      font-family: var(--font-body);
      font-weight: 400;
      line-height: 1.7;
      overflow-x: hidden;
      cursor: default;
    }

    ::selection {
      background: rgba(181, 123, 238, 0.3);
      color: #fff;
    }

    /* SCROLLBAR */
    ::-webkit-scrollbar {
      width: 4px;
    }

    ::-webkit-scrollbar-track {
      background: var(--bg);
    }

    ::-webkit-scrollbar-thumb {
      background: var(--purple-dim);
      border-radius: 2px;
    }

    /* ---- GLOBAL PROGRESS BAR ---- */
    #progress-bar {
      position: fixed;
      top: 0;
      left: 0;
      z-index: 1000;
      height: 2px;
      width: 0%;
      background: linear-gradient(90deg, var(--purple), var(--pink));
      transition: width 0.1s linear;
      box-shadow: 0 0 12px var(--purple);
    }

    /* ---- DOT NAVIGATION ---- */
    #dot-nav {
      position: fixed;
      right: 24px;
      top: 50%;
      transform: translateY(-50%);
      z-index: 900;
      display: flex;
      flex-direction: column;
      gap: 10px;
    }

    .dot {
      width: 8px;
      height: 8px;
      border-radius: 50%;
      background: var(--text-3);
      border: none;
      cursor: pointer;
      transition: var(--transition);
      padding: 0;
      position: relative;
    }

    .dot.active {
      background: var(--purple);
      transform: scale(1.6);
      box-shadow: 0 0 12px var(--purple);
    }

    .dot:hover {
      background: var(--text-2);
      transform: scale(1.3);
    }

    .dot-label {
      position: absolute;
      right: 18px;
      top: 50%;
      transform: translateY(-50%);
      background: var(--bg-2);
      color: var(--text-2);
      font-size: 11px;
      font-family: var(--font-mono);
      padding: 4px 10px;
      border-radius: 4px;
      white-space: nowrap;
      opacity: 0;
      pointer-events: none;
      border: 1px solid var(--border);
      transition: opacity 0.2s;
    }

    .dot:hover .dot-label {
      opacity: 1;
    }

    /* ---- SECTIONS ---- */
    section {
      min-height: 100vh;
      padding: 100px 0;
      position: relative;
      overflow: hidden;
    }

    .container {
      max-width: 1200px;
      margin: 0 auto;
      padding: 0 48px;
    }

    /* ---- TYPE SYSTEM ---- */
    .display {
      font-family: var(--font-display);
      font-size: clamp(3rem, 7vw, 7rem);
      line-height: 1.05;
      letter-spacing: -0.02em;
      color: var(--text-1);
    }

    .display em {
      font-style: italic;
      color: var(--purple);
    }

    .section-label {
      font-family: var(--font-mono);
      font-size: 11px;
      letter-spacing: 0.2em;
      text-transform: uppercase;
      color: var(--purple);
      margin-bottom: 16px;
      display: flex;
      align-items: center;
      gap: 12px;
    }

    .section-label::before {
      content: '';
      display: block;
      width: 32px;
      height: 1px;
      background: var(--purple);
    }

    .section-title {
      font-family: var(--font-display);
      font-size: clamp(2rem, 4vw, 3.5rem);
      line-height: 1.1;
      letter-spacing: -0.02em;
      color: var(--text-1);
      margin-bottom: 20px;
    }

    .section-title em {
      font-style: italic;
      color: var(--purple);
    }

    .lead {
      font-size: 1.15rem;
      color: var(--text-2);
      max-width: 640px;
      line-height: 1.8;
    }

    /* ---- CARDS ---- */
    .card {
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      padding: 28px 32px;
      box-shadow: var(--shadow-card);
      transition: var(--transition);
      position: relative;
      overflow: hidden;
    }

    .card::before {
      content: '';
      position: absolute;
      inset: 0;
      background: linear-gradient(135deg, var(--purple-glow) 0%, transparent 60%);
      opacity: 0;
      transition: opacity 0.4s;
    }

    .card:hover::before {
      opacity: 1;
    }

    .card:hover {
      border-color: rgba(181, 123, 238, 0.3);
      transform: translateY(-3px);
      box-shadow: var(--shadow-card), var(--shadow-glow);
    }

    /* ---- BADGE ---- */
    .badge {
      display: inline-flex;
      align-items: center;
      gap: 6px;
      font-family: var(--font-mono);
      font-size: 11px;
      letter-spacing: 0.1em;
      text-transform: uppercase;
      padding: 5px 12px;
      border-radius: 100px;
      border: 1px solid;
      font-weight: 500;
    }

    .badge-purple {
      color: var(--purple);
      border-color: rgba(181, 123, 238, 0.3);
      background: rgba(181, 123, 238, 0.08);
    }

    .badge-pink {
      color: var(--pink);
      border-color: rgba(240, 98, 146, 0.3);
      background: rgba(240, 98, 146, 0.08);
    }

    .badge-teal {
      color: var(--teal);
      border-color: rgba(77, 208, 225, 0.3);
      background: rgba(77, 208, 225, 0.08);
    }

    .badge-amber {
      color: var(--amber);
      border-color: rgba(255, 183, 77, 0.3);
      background: rgba(255, 183, 77, 0.08);
    }

    .badge-red {
      color: var(--red);
      border-color: rgba(239, 83, 80, 0.3);
      background: rgba(239, 83, 80, 0.08);
    }

    .badge-green {
      color: var(--green);
      border-color: rgba(102, 187, 106, 0.3);
      background: rgba(102, 187, 106, 0.08);
    }

    /* ---- GRID LAYOUTS ---- */
    .grid-2 {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: 24px;
    }

    .grid-3 {
      display: grid;
      grid-template-columns: repeat(3, 1fr);
      gap: 20px;
    }

    .grid-4 {
      display: grid;
      grid-template-columns: repeat(4, 1fr);
      gap: 18px;
    }

    @media (max-width: 900px) {

      .grid-2,
      .grid-3,
      .grid-4 {
        grid-template-columns: 1fr;
      }

      .container {
        padding: 0 24px;
      }

      section {
        padding: 80px 0;
      }
    }

    /* ---- ANIMATED ORBS ---- */
    .orb {
      position: absolute;
      border-radius: 50%;
      filter: blur(80px);
      opacity: 0.4;
      animation: float 8s ease-in-out infinite;
      pointer-events: none;
    }

    .orb-1 {
      width: 500px;
      height: 500px;
      background: radial-gradient(circle, var(--purple-dim), transparent 70%);
    }

    .orb-2 {
      width: 400px;
      height: 400px;
      background: radial-gradient(circle, #c2185b, transparent 70%);
      animation-delay: -3s;
    }

    .orb-3 {
      width: 350px;
      height: 350px;
      background: radial-gradient(circle, #00838f, transparent 70%);
      animation-delay: -6s;
    }

    @keyframes float {

      0%,
      100% {
        transform: translate(0, 0) scale(1);
      }

      33% {
        transform: translate(20px, -30px) scale(1.05);
      }

      66% {
        transform: translate(-15px, 20px) scale(0.95);
      }
    }

    /* ---- DIVIDERS ---- */
    .section-divider {
      height: 1px;
      background: linear-gradient(90deg, transparent, var(--border), transparent);
      margin: 80px 0;
    }

    /* ---- STAT COUNTER ---- */
    .stat-block {
      text-align: center;
    }

    .stat-number {
      font-family: var(--font-display);
      font-size: clamp(2.5rem, 5vw, 4.5rem);
      color: var(--purple);
      line-height: 1;
      text-shadow: 0 0 40px rgba(181, 123, 238, 0.5);
    }

    .stat-label {
      font-size: 0.85rem;
      color: var(--text-2);
      margin-top: 8px;
      font-family: var(--font-mono);
      letter-spacing: 0.05em;
    }

    /* ---- SCROLL INDICATOR ---- */
    .scroll-indicator {
      position: absolute;
      bottom: 40px;
      left: 50%;
      transform: translateX(-50%);
      display: flex;
      flex-direction: column;
      align-items: center;
      gap: 8px;
      color: var(--text-3);
      font-size: 11px;
      font-family: var(--font-mono);
      letter-spacing: 0.15em;
      text-transform: uppercase;
      animation: bounce 2s ease-in-out infinite;
    }

    .scroll-arrow {
      width: 1px;
      height: 40px;
      background: linear-gradient(180deg, transparent, var(--purple));
    }

    @keyframes bounce {

      0%,
      100% {
        transform: translateX(-50%) translateY(0);
      }

      50% {
        transform: translateX(-50%) translateY(6px);
      }
    }

    /* ---- GSAP REVEAL SETUP ---- */
    .reveal {
      opacity: 0;
    }

    /* ============================================================
   SECTION 0 — HERO
   ============================================================ */
    #hero {
      min-height: 100vh;
      display: flex;
      align-items: center;
      background: var(--bg);
      position: relative;
    }

    .hero-bg {
      position: absolute;
      inset: 0;
      pointer-events: none;
      overflow: hidden;
    }

    .hero-grid {
      position: absolute;
      inset: 0;
      background-image:
        linear-gradient(rgba(181, 123, 238, 0.04) 1px, transparent 1px),
        linear-gradient(90deg, rgba(181, 123, 238, 0.04) 1px, transparent 1px);
      background-size: 60px 60px;
      mask-image: radial-gradient(ellipse 80% 80% at 50% 50%, black 40%, transparent 100%);
    }

    .hero-content {
      position: relative;
      z-index: 2;
      max-width: 900px;
    }

    .hero-eyebrow {
      font-family: var(--font-mono);
      font-size: 11px;
      letter-spacing: 0.25em;
      text-transform: uppercase;
      color: var(--purple);
      display: flex;
      align-items: center;
      gap: 16px;
      margin-bottom: 32px;
    }

    .hero-eyebrow::after {
      content: '';
      flex: 1;
      max-width: 120px;
      height: 1px;
      background: linear-gradient(90deg, var(--purple), transparent);
    }

    .hero-title {
      font-family: var(--font-display);
      font-size: clamp(3.5rem, 9vw, 9rem);
      line-height: 0.95;
      letter-spacing: -0.03em;
      margin-bottom: 24px;
    }

    .hero-title .line-1 {
      display: block;
      color: var(--text-1);
    }

    .hero-title .line-2 {
      display: block;
      color: transparent;
      -webkit-text-stroke: 1px rgba(181, 123, 238, 0.5);
      font-style: italic;
    }

    .hero-subtitle {
      font-size: 1.1rem;
      color: var(--text-2);
      max-width: 540px;
      line-height: 1.8;
      margin-bottom: 48px;
    }

    .hero-tags {
      display: flex;
      flex-wrap: wrap;
      gap: 10px;
      margin-bottom: 48px;
    }

    .hero-stat-row {
      display: grid;
      grid-template-columns: repeat(3, auto);
      gap: 40px;
      width: fit-content;
      padding-top: 32px;
      border-top: 1px solid var(--border);
    }

    /* Uterus SVG animation */
    .uterus-float {
      position: absolute;
      right: 5%;
      top: 50%;
      transform: translateY(-50%);
      width: 380px;
      opacity: 0.7;
      animation: uterus-pulse 4s ease-in-out infinite;
      z-index: 1;
    }

    @keyframes uterus-pulse {

      0%,
      100% {
        transform: translateY(-50%) scale(1);
        filter: drop-shadow(0 0 30px rgba(181, 123, 238, 0.3));
      }

      50% {
        transform: translateY(-52%) scale(1.02);
        filter: drop-shadow(0 0 60px rgba(181, 123, 238, 0.5));
      }
    }

    @media (max-width: 900px) {
      .uterus-float {
        display: none;
      }
    }

    /* ============================================================
   SECTION 1 — EPIDEMIOLOGY
   ============================================================ */
    #epidemiology {
      background: linear-gradient(180deg, var(--bg) 0%, var(--bg-1) 100%);
    }

    .epi-grid {
      display: grid;
      grid-template-columns: 1fr 1.2fr;
      gap: 60px;
      align-items: center;
    }

    .stat-cards {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: 16px;
    }

    .stat-card {
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      padding: 24px;
      text-align: center;
      position: relative;
      overflow: hidden;
    }

    .stat-card::after {
      content: '';
      position: absolute;
      bottom: 0;
      left: 0;
      right: 0;
      height: 2px;
      background: linear-gradient(90deg, transparent, var(--purple), transparent);
    }

    .race-bar-section {
      margin-top: 32px;
    }

    .race-bar-label {
      display: flex;
      justify-content: space-between;
      font-size: 0.8rem;
      color: var(--text-2);
      font-family: var(--font-mono);
      margin-bottom: 6px;
    }

    .race-bar {
      height: 8px;
      border-radius: 4px;
      background: var(--bg-2);
      overflow: hidden;
      margin-bottom: 14px;
    }

    .race-bar-fill {
      height: 100%;
      border-radius: 4px;
      width: 0;
      transition: width 1.5s cubic-bezier(0.16, 1, 0.3, 1);
    }

    .bar-black {
      background: linear-gradient(90deg, var(--purple), var(--pink));
    }

    .bar-white {
      background: linear-gradient(90deg, var(--teal), var(--purple));
    }

    .bar-hisp {
      background: linear-gradient(90deg, var(--amber), var(--teal));
    }

    .bar-asian {
      background: linear-gradient(90deg, var(--green), var(--teal));
    }

    /* ============================================================
   SECTION 2 — PATHOPHYSIOLOGY
   ============================================================ */
    #pathophysiology {
      background: var(--bg-1);
    }

    .pathway-flow {
      display: flex;
      align-items: center;
      gap: 0;
      margin: 48px 0;
      flex-wrap: wrap;
    }

    .pathway-node {
      background: var(--bg-card-2);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      padding: 20px 24px;
      text-align: center;
      flex: 1;
      min-width: 160px;
      position: relative;
    }

    .pathway-node .node-icon {
      font-size: 2rem;
      margin-bottom: 10px;
    }

    .pathway-node h4 {
      font-size: 0.85rem;
      font-weight: 600;
      color: var(--text-1);
      margin-bottom: 4px;
    }

    .pathway-node p {
      font-size: 0.75rem;
      color: var(--text-2);
    }

    .pathway-arrow {
      color: var(--purple);
      font-size: 1.5rem;
      padding: 0 8px;
      flex-shrink: 0;
    }

    .gene-cards {
      display: grid;
      grid-template-columns: repeat(4, 1fr);
      gap: 16px;
      margin-top: 32px;
    }

    .gene-card {
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius-sm);
      padding: 20px;
    }

    .gene-name {
      font-family: var(--font-mono);
      font-size: 1rem;
      color: var(--teal);
      font-weight: 500;
      margin-bottom: 6px;
    }

    .gene-freq {
      font-family: var(--font-display);
      font-size: 2rem;
      color: var(--purple);
      line-height: 1;
      margin-bottom: 8px;
    }

    @media (max-width:900px) {
      .gene-cards {
        grid-template-columns: 1fr 1fr;
      }

      .pathway-flow {
        flex-direction: column;
        gap: 8px;
      }

      .pathway-arrow {
        transform: rotate(90deg);
      }

      .epi-grid {
        grid-template-columns: 1fr;
      }
    }

    /* ============================================================
   SECTION 3 — CLASSIFICATION (TYPES)
   ============================================================ */
    #classification {
      background: linear-gradient(180deg, var(--bg-1) 0%, var(--bg) 100%);
    }

    .fibroid-explorer {
      display: grid;
      grid-template-columns: 1fr 1.2fr;
      gap: 40px;
      align-items: start;
    }

    .type-tabs {
      display: flex;
      flex-direction: column;
      gap: 12px;
    }

    .type-tab {
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      padding: 20px 24px;
      cursor: pointer;
      transition: var(--transition);
      border-left: 3px solid transparent;
    }

    .type-tab:hover {
      border-color: rgba(181, 123, 238, 0.3);
    }

    .type-tab.active {
      border-left-color: var(--purple);
      background: var(--bg-card-2);
      box-shadow: var(--shadow-glow);
    }

    .type-tab h4 {
      font-size: 1rem;
      font-weight: 600;
      margin-bottom: 4px;
      color: var(--text-1);
    }

    .type-tab p {
      font-size: 0.8rem;
      color: var(--text-2);
    }

    .type-detail-panel {
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius-lg);
      padding: 32px;
      position: sticky;
      top: 120px;
    }

    .uterus-diagram {
      width: 100%;
      max-width: 320px;
      margin: 0 auto 24px;
      display: block;
    }

    .detail-tag {
      margin-bottom: 16px;
    }

    .detail-title {
      font-family: var(--font-display);
      font-size: 2rem;
      margin-bottom: 12px;
    }

    .detail-body {
      font-size: 0.9rem;
      color: var(--text-2);
      line-height: 1.8;
    }

    .detail-list {
      list-style: none;
      margin-top: 16px;
    }

    .detail-list li {
      padding: 8px 0;
      border-bottom: 1px solid var(--border-2);
      font-size: 0.85rem;
      color: var(--text-2);
      display: flex;
      align-items: flex-start;
      gap: 10px;
    }

    .detail-list li::before {
      content: '→';
      color: var(--purple);
      flex-shrink: 0;
    }

    /* ============================================================
   SECTION 4 — FIGO CLASSIFICATION
   ============================================================ */
    #figo {
      background: var(--bg);
    }

    .figo-grid {
      display: grid;
      grid-template-columns: repeat(3, 1fr);
      gap: 16px;
      margin-top: 48px;
    }

    .figo-card {
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      padding: 20px;
      cursor: pointer;
      transition: var(--transition);
      position: relative;
      overflow: hidden;
    }

    .figo-card::before {
      content: '';
      position: absolute;
      top: 0;
      left: 0;
      right: 0;
      height: 2px;
      background: linear-gradient(90deg, transparent, var(--purple), transparent);
      transform: scaleX(0);
      transition: transform 0.4s;
    }

    .figo-card:hover::before,
    .figo-card.active::before {
      transform: scaleX(1);
    }

    .figo-card.active {
      border-color: rgba(181, 123, 238, 0.4);
      background: var(--bg-card-2);
    }

    .figo-number {
      font-family: var(--font-display);
      font-size: 3rem;
      color: var(--purple);
      line-height: 1;
      margin-bottom: 8px;
      opacity: 0.8;
    }

    .figo-name {
      font-size: 0.8rem;
      font-weight: 600;
      color: var(--text-1);
      margin-bottom: 6px;
    }

    .figo-desc {
      font-size: 0.75rem;
      color: var(--text-2);
      line-height: 1.6;
    }

    .figo-location {
      display: inline-flex;
      margin-top: 10px;
    }

    .figo-detail-panel {
      margin-top: 32px;
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius-lg);
      padding: 32px;
      display: none;
    }

    .figo-detail-panel.visible {
      display: block;
    }

    @media (max-width:900px) {
      .figo-grid {
        grid-template-columns: 1fr 1fr;
      }
    }

    /* ============================================================
   SECTION 5 — SYMPTOMS
   ============================================================ */
    #symptoms {
      background: linear-gradient(180deg, var(--bg) 0%, var(--bg-1) 100%);
    }

    .symptom-categories {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: 24px;
      margin-top: 48px;
    }

    .symptom-cat {}

    .symptom-cat-title {
      font-family: var(--font-mono);
      font-size: 11px;
      letter-spacing: 0.15em;
      text-transform: uppercase;
      color: var(--text-3);
      margin-bottom: 16px;
      padding-bottom: 8px;
      border-bottom: 1px solid var(--border-2);
    }

    .symptom-item {
      display: flex;
      align-items: flex-start;
      gap: 14px;
      padding: 14px 0;
      border-bottom: 1px solid var(--border-2);
    }

    .symptom-icon {
      font-size: 1.2rem;
      flex-shrink: 0;
      width: 28px;
      text-align: center;
    }

    .symptom-text h5 {
      font-size: 0.9rem;
      font-weight: 600;
      color: var(--text-1);
      margin-bottom: 2px;
    }

    .symptom-text p {
      font-size: 0.8rem;
      color: var(--text-2);
    }

    .severity-dot {
      width: 8px;
      height: 8px;
      border-radius: 50%;
      margin-top: 5px;
      flex-shrink: 0;
    }

    .sev-high {
      background: var(--red);
      box-shadow: 0 0 6px var(--red);
    }

    .sev-med {
      background: var(--amber);
      box-shadow: 0 0 6px var(--amber);
    }

    .sev-low {
      background: var(--green);
      box-shadow: 0 0 6px var(--green);
    }

    .asymptomatic-callout {
      margin-top: 32px;
      padding: 24px 32px;
      background: linear-gradient(135deg, rgba(77, 208, 225, 0.08) 0%, rgba(181, 123, 238, 0.05) 100%);
      border: 1px solid rgba(77, 208, 225, 0.2);
      border-radius: var(--radius);
      display: flex;
      align-items: center;
      gap: 20px;
    }

    .callout-big {
      font-family: var(--font-display);
      font-size: 4rem;
      color: var(--teal);
      flex-shrink: 0;
    }

    /* ============================================================
   SECTION 6 — COMPLICATIONS
   ============================================================ */
    #complications {
      background: var(--bg-1);
    }

    .complication-cards {
      display: grid;
      grid-template-columns: repeat(3, 1fr);
      gap: 20px;
      margin-top: 48px;
    }

    .comp-card {
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      padding: 24px;
      position: relative;
    }

    .comp-icon {
      font-size: 2rem;
      margin-bottom: 16px;
    }

    .comp-title {
      font-size: 1rem;
      font-weight: 600;
      margin-bottom: 10px;
    }

    .comp-items {
      list-style: none;
    }

    .comp-items li {
      font-size: 0.82rem;
      color: var(--text-2);
      padding: 5px 0;
      border-bottom: 1px solid var(--border-2);
      display: flex;
      align-items: flex-start;
      gap: 8px;
    }

    .comp-items li::before {
      content: '▸';
      color: var(--purple);
    }

    .pearl-callout {
      margin-top: 32px;
      padding: 24px 32px;
      background: linear-gradient(135deg, rgba(239, 83, 80, 0.08) 0%, rgba(181, 123, 238, 0.05) 100%);
      border: 1px solid rgba(239, 83, 80, 0.25);
      border-radius: var(--radius);
      border-left: 3px solid var(--red);
    }

    .pearl-callout .pearl-title {
      font-family: var(--font-mono);
      font-size: 11px;
      letter-spacing: 0.15em;
      text-transform: uppercase;
      color: var(--red);
      margin-bottom: 10px;
    }

    @media (max-width:900px) {
      .complication-cards {
        grid-template-columns: 1fr;
      }
    }

    /* ============================================================
   SECTION 7 — DIFFERENTIAL DIAGNOSIS
   ============================================================ */
    #differential {
      background: var(--bg);
    }

    .diff-table {
      width: 100%;
      border-collapse: collapse;
      margin-top: 40px;
      font-size: 0.875rem;
    }

    .diff-table th {
      text-align: left;
      font-family: var(--font-mono);
      font-size: 10px;
      letter-spacing: 0.15em;
      text-transform: uppercase;
      color: var(--text-3);
      padding: 12px 16px;
      border-bottom: 1px solid var(--border);
    }

    .diff-table td {
      padding: 14px 16px;
      border-bottom: 1px solid var(--border-2);
      color: var(--text-2);
      vertical-align: top;
    }

    .diff-table tr:hover td {
      background: rgba(181, 123, 238, 0.04);
      color: var(--text-1);
    }

    .diff-table td:first-child {
      color: var(--text-1);
      font-weight: 500;
    }

    .diff-table .key-diff {
      color: var(--amber);
      font-style: italic;
      font-size: 0.8rem;
    }

    /* ============================================================
   SECTION 8 — DIAGNOSIS WORKFLOW
   ============================================================ */
    #diagnosis {
      background: linear-gradient(180deg, var(--bg) 0%, var(--bg-1) 100%);
    }

    .dx-flow {
      margin-top: 48px;
      position: relative;
    }

    .dx-step {
      display: flex;
      gap: 24px;
      align-items: flex-start;
      padding: 0 0 40px 0;
      position: relative;
      opacity: 0;
      transform: translateX(-20px);
    }

    .dx-step.revealed {
      opacity: 1;
      transform: none;
      transition: var(--transition);
    }

    .dx-step-line {
      position: absolute;
      left: 27px;
      top: 55px;
      bottom: 0;
      width: 1px;
      background: linear-gradient(180deg, var(--purple), transparent);
    }

    .dx-step:last-child .dx-step-line {
      display: none;
    }

    .dx-number {
      width: 54px;
      height: 54px;
      border-radius: 50%;
      background: var(--bg-card-2);
      border: 1px solid var(--border);
      display: flex;
      align-items: center;
      justify-content: center;
      font-family: var(--font-display);
      font-size: 1.4rem;
      color: var(--purple);
      flex-shrink: 0;
      transition: var(--transition);
      position: relative;
      z-index: 1;
    }

    .dx-step.active .dx-number {
      background: rgba(181, 123, 238, 0.15);
      border-color: var(--purple);
      box-shadow: 0 0 24px rgba(181, 123, 238, 0.3);
    }

    .dx-content {
      flex: 1;
      padding-top: 12px;
    }

    .dx-content h4 {
      font-size: 1rem;
      font-weight: 600;
      margin-bottom: 6px;
    }

    .dx-content p {
      font-size: 0.85rem;
      color: var(--text-2);
      margin-bottom: 8px;
    }

    .dx-detail {
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius-sm);
      padding: 14px 18px;
      margin-top: 8px;
      font-size: 0.82rem;
      color: var(--text-2);
    }

    .dx-indications {
      display: flex;
      flex-wrap: wrap;
      gap: 8px;
      margin-top: 8px;
    }

    /* ============================================================
   SECTION 9 — MANAGEMENT ALGORITHM
   ============================================================ */
    #management {
      background: var(--bg-1);
    }

    .mgmt-decision {
      margin-top: 48px;
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius-lg);
      padding: 40px;
      overflow-x: auto;
    }

    .mgmt-tree {
      font-family: var(--font-mono);
      font-size: 0.8rem;
      color: var(--text-2);
      white-space: pre;
      line-height: 2;
    }

    .tree-root {
      color: var(--text-1);
      font-size: 0.95rem;
      font-weight: 500;
    }

    .tree-branch {
      color: var(--purple);
    }

    .tree-leaf {
      color: var(--teal);
    }

    .tree-action {
      color: var(--pink);
    }

    .mgmt-pathways {
      display: grid;
      grid-template-columns: repeat(4, 1fr);
      gap: 16px;
      margin-top: 32px;
    }

    .pathway-card {
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      padding: 24px;
      border-top: 3px solid;
    }

    .pathway-card.expectant {
      border-top-color: var(--green);
    }

    .pathway-card.medical {
      border-top-color: var(--teal);
    }

    .pathway-card.interv {
      border-top-color: var(--amber);
    }

    .pathway-card.surgical {
      border-top-color: var(--pink);
    }

    .pathway-card h4 {
      font-family: var(--font-mono);
      font-size: 11px;
      letter-spacing: 0.12em;
      text-transform: uppercase;
      margin-bottom: 16px;
    }

    .pathway-card.expectant h4 {
      color: var(--green);
    }

    .pathway-card.medical h4 {
      color: var(--teal);
    }

    .pathway-card.interv h4 {
      color: var(--amber);
    }

    .pathway-card.surgical h4 {
      color: var(--pink);
    }

    .pathway-card ul {
      list-style: none;
    }

    .pathway-card ul li {
      font-size: 0.8rem;
      color: var(--text-2);
      padding: 5px 0;
      border-bottom: 1px solid var(--border-2);
      display: flex;
      align-items: flex-start;
      gap: 8px;
    }

    .pathway-card ul li::before {
      content: '·';
      color: inherit;
      font-size: 1.2rem;
      line-height: 1;
    }

    @media (max-width:900px) {
      .mgmt-pathways {
        grid-template-columns: 1fr 1fr;
      }
    }

    /* ============================================================
   SECTION 10 — DRUGS
   ============================================================ */
    #drugs {
      background: var(--bg);
    }

    .drugs-grid {
      display: grid;
      grid-template-columns: repeat(3, 1fr);
      gap: 20px;
      margin-top: 48px;
    }

    .drug-card {
      height: 260px;
      perspective: 1000px;
      cursor: pointer;
    }

    .drug-card-inner {
      width: 100%;
      height: 100%;
      transition: transform 0.7s cubic-bezier(0.16, 1, 0.3, 1);
      transform-style: preserve-3d;
      position: relative;
    }

    .drug-card:hover .drug-card-inner,
    .drug-card.flipped .drug-card-inner {
      transform: rotateY(180deg);
    }

    .drug-front,
    .drug-back {
      position: absolute;
      inset: 0;
      backface-visibility: hidden;
      -webkit-backface-visibility: hidden;
      border-radius: var(--radius);
      padding: 28px;
      border: 1px solid var(--border);
      display: flex;
      flex-direction: column;
      justify-content: space-between;
    }

    .drug-front {
      background: var(--bg-card);
    }

    .drug-back {
      background: var(--bg-card-2);
      transform: rotateY(180deg);
      border-color: rgba(181, 123, 238, 0.25);
    }

    .drug-class {
      font-family: var(--font-mono);
      font-size: 10px;
      letter-spacing: 0.15em;
      text-transform: uppercase;
      color: var(--text-3);
      margin-bottom: 10px;
    }

    .drug-name {
      font-family: var(--font-display);
      font-size: 1.6rem;
      margin-bottom: 8px;
    }

    .drug-example {
      font-size: 0.8rem;
      color: var(--purple);
      font-family: var(--font-mono);
    }

    .drug-flip-hint {
      font-size: 10px;
      color: var(--text-3);
      font-family: var(--font-mono);
      align-self: flex-end;
    }

    .drug-back h5 {
      font-size: 0.8rem;
      font-family: var(--font-mono);
      color: var(--purple);
      margin-bottom: 10px;
    }

    .drug-back ul {
      list-style: none;
      flex: 1;
      overflow-y: auto;
    }

    .drug-back ul li {
      font-size: 0.78rem;
      color: var(--text-2);
      padding: 5px 0;
      border-bottom: 1px solid var(--border-2);
      display: flex;
      gap: 8px;
    }

    .drug-back ul li::before {
      content: '→';
      color: var(--purple);
    }

    .drug-warning {
      font-size: 0.72rem;
      color: var(--red);
      margin-top: 10px;
      padding: 6px 10px;
      border: 1px solid rgba(239, 83, 80, 0.2);
      border-radius: var(--radius-sm);
      background: rgba(239, 83, 80, 0.05);
    }

    @media (max-width:900px) {
      .drugs-grid {
        grid-template-columns: 1fr 1fr;
      }
    }

    /* ============================================================
   SECTION 11 — PROCEDURES
   ============================================================ */
    #procedures {
      background: linear-gradient(180deg, var(--bg) 0%, var(--bg-1) 100%);
    }

    .proc-timeline {
      margin-top: 48px;
      position: relative;
      display: grid;
      grid-template-columns: repeat(5, 1fr);
      gap: 0;
    }

    .proc-timeline::before {
      content: '';
      position: absolute;
      top: 27px;
      left: 27px;
      right: 27px;
      height: 1px;
      background: linear-gradient(90deg, var(--purple), var(--pink));
      z-index: 0;
    }

    .proc-item {
      position: relative;
      z-index: 1;
      text-align: center;
      padding-top: 60px;
      padding-left: 10px;
      padding-right: 10px;
    }

    .proc-dot {
      width: 54px;
      height: 54px;
      border-radius: 50%;
      background: var(--bg-card-2);
      border: 2px solid var(--purple);
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.4rem;
      margin: 0 auto 16px;
      position: absolute;
      top: 0;
      left: 50%;
      transform: translateX(-50%);
      transition: var(--transition);
    }

    .proc-item:hover .proc-dot {
      background: rgba(181, 123, 238, 0.2);
      box-shadow: 0 0 24px rgba(181, 123, 238, 0.4);
    }

    .proc-name {
      font-size: 0.8rem;
      font-weight: 600;
      color: var(--text-1);
      margin-bottom: 8px;
    }

    .proc-desc {
      font-size: 0.73rem;
      color: var(--text-2);
      line-height: 1.6;
    }

    .proc-type {
      font-family: var(--font-mono);
      font-size: 9px;
      letter-spacing: 0.12em;
      text-transform: uppercase;
      color: var(--text-3);
      margin-bottom: 6px;
    }

    @media (max-width:900px) {
      .proc-timeline {
        grid-template-columns: 1fr 1fr;
        margin-top: 80px;
      }

      .proc-timeline::before {
        display: none;
      }

      .proc-item {
        padding-top: 70px;
      }
    }

    /* ============================================================
   SECTION 12 — EMERGENCY
   ============================================================ */
    #emergency {
      background: var(--bg-1);
      border-top: 1px solid rgba(239, 83, 80, 0.15);
      border-bottom: 1px solid rgba(239, 83, 80, 0.15);
    }

    .emergency-header {
      display: flex;
      align-items: center;
      gap: 20px;
      margin-bottom: 48px;
    }

    .emergency-pulse {
      width: 60px;
      height: 60px;
      border-radius: 50%;
      background: rgba(239, 83, 80, 0.15);
      border: 2px solid var(--red);
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.8rem;
      animation: emergency-pulse 1.5s ease-in-out infinite;
    }

    @keyframes emergency-pulse {

      0%,
      100% {
        box-shadow: 0 0 0 0 rgba(239, 83, 80, 0.4);
      }

      50% {
        box-shadow: 0 0 0 20px rgba(239, 83, 80, 0);
      }
    }

    .emergency-title {
      font-family: var(--font-display);
      font-size: 2.5rem;
      color: var(--red);
    }

    .emergency-steps {
      display: grid;
      grid-template-columns: repeat(4, 1fr);
      gap: 16px;
    }

    .emstep {
      background: var(--bg-card);
      border: 1px solid rgba(239, 83, 80, 0.2);
      border-radius: var(--radius);
      padding: 24px;
      border-top: 3px solid var(--red);
    }

    .emstep-num {
      font-family: var(--font-display);
      font-size: 2.5rem;
      color: var(--red);
      opacity: 0.3;
      line-height: 1;
      margin-bottom: 12px;
    }

    .emstep h4 {
      font-size: 0.9rem;
      font-weight: 600;
      margin-bottom: 8px;
    }

    .emstep ul {
      list-style: none;
    }

    .emstep ul li {
      font-size: 0.78rem;
      color: var(--text-2);
      padding: 4px 0;
      display: flex;
      gap: 8px;
    }

    .emstep ul li::before {
      content: '▸';
      color: var(--red);
    }

    @media (max-width:900px) {
      .emergency-steps {
        grid-template-columns: 1fr 1fr;
      }
    }

    /* ============================================================
   SECTION 13 — EXAM PEARLS
   ============================================================ */
    #pearls {
      background: var(--bg);
    }

    .pearl-list {
      margin-top: 48px;
      display: flex;
      flex-direction: column;
      gap: 12px;
    }

    .pearl-item {
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      overflow: hidden;
      transition: var(--transition);
    }

    .pearl-header {
      display: flex;
      align-items: center;
      gap: 16px;
      padding: 20px 24px;
      cursor: pointer;
      user-select: none;
    }

    .pearl-num {
      font-family: var(--font-display);
      font-size: 1.6rem;
      color: var(--purple);
      opacity: 0.5;
      width: 40px;
      flex-shrink: 0;
    }

    .pearl-question {
      font-size: 0.95rem;
      font-weight: 500;
      flex: 1;
    }

    .pearl-toggle {
      color: var(--text-3);
      font-size: 1.2rem;
      transition: transform 0.3s;
      flex-shrink: 0;
    }

    .pearl-item.open .pearl-toggle {
      transform: rotate(45deg);
      color: var(--purple);
    }

    .pearl-body {
      max-height: 0;
      overflow: hidden;
      transition: max-height 0.5s cubic-bezier(0.16, 1, 0.3, 1);
      padding: 0 24px 0 80px;
    }

    .pearl-item.open .pearl-body {
      max-height: 400px;
      padding: 0 24px 20px 80px;
    }

    .pearl-answer {
      font-size: 0.85rem;
      color: var(--text-2);
      line-height: 1.8;
      border-top: 1px solid var(--border-2);
      padding-top: 16px;
    }

    .pearl-answer strong {
      color: var(--purple);
    }

    /* ============================================================
   SECTION 14 — QUIZ
   ============================================================ */
    #quiz {
      background: linear-gradient(180deg, var(--bg) 0%, var(--bg-1) 100%);
    }

    .quiz-container {
      max-width: 780px;
      margin: 0 auto;
    }

    .quiz-progress {
      display: flex;
      gap: 8px;
      margin-bottom: 48px;
    }

    .quiz-progress-dot {
      flex: 1;
      height: 4px;
      border-radius: 2px;
      background: var(--bg-2);
      transition: background 0.4s;
    }

    .quiz-progress-dot.done {
      background: var(--green);
    }

    .quiz-progress-dot.active {
      background: var(--purple);
    }

    .quiz-question-num {
      font-family: var(--font-mono);
      font-size: 11px;
      letter-spacing: 0.15em;
      text-transform: uppercase;
      color: var(--text-3);
      margin-bottom: 16px;
    }

    .quiz-question {
      font-family: var(--font-display);
      font-size: 1.6rem;
      line-height: 1.3;
      margin-bottom: 32px;
      color: var(--text-1);
    }

    .quiz-options {
      display: flex;
      flex-direction: column;
      gap: 12px;
    }

    .quiz-option {
      background: var(--bg-card);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      padding: 16px 20px;
      cursor: pointer;
      transition: var(--transition);
      display: flex;
      align-items: center;
      gap: 14px;
      font-size: 0.9rem;
      color: var(--text-2);
    }

    .quiz-option:hover {
      border-color: rgba(181, 123, 238, 0.3);
      color: var(--text-1);
    }

    .quiz-option.correct {
      border-color: rgba(102, 187, 106, 0.5);
      background: rgba(102, 187, 106, 0.08);
      color: var(--green);
      animation: correct-bounce 0.5s ease;
    }

    .quiz-option.incorrect {
      border-color: rgba(239, 83, 80, 0.4);
      background: rgba(239, 83, 80, 0.06);
      color: var(--red);
      animation: wrong-shake 0.5s ease;
    }

    @keyframes correct-bounce {

      0%,
      100% {
        transform: scale(1);
      }

      50% {
        transform: scale(1.02);
      }
    }

    @keyframes wrong-shake {

      0%,
      100% {
        transform: translateX(0);
      }

      25% {
        transform: translateX(-6px);
      }

      75% {
        transform: translateX(6px);
      }
    }

    .quiz-opt-letter {
      width: 28px;
      height: 28px;
      border-radius: 50%;
      background: var(--bg-2);
      border: 1px solid var(--border);
      display: flex;
      align-items: center;
      justify-content: center;
      font-family: var(--font-mono);
      font-size: 0.75rem;
      flex-shrink: 0;
    }

    .quiz-explanation {
      margin-top: 20px;
      padding: 20px 24px;
      background: var(--bg-card-2);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      display: none;
      font-size: 0.85rem;
      color: var(--text-2);
      line-height: 1.8;
      border-left: 3px solid var(--purple);
    }

    .quiz-explanation.visible {
      display: block;
      animation: fadeIn 0.4s ease;
    }

    .quiz-explanation strong {
      color: var(--purple);
    }

    @keyframes fadeIn {
      from {
        opacity: 0;
        transform: translateY(8px);
      }

      to {
        opacity: 1;
        transform: none;
      }
    }

    .quiz-nav {
      display: flex;
      justify-content: space-between;
      align-items: center;
      margin-top: 32px;
    }

    .btn {
      background: transparent;
      border: 1px solid var(--border);
      color: var(--text-1);
      padding: 12px 28px;
      border-radius: 100px;
      font-family: var(--font-body);
      font-size: 0.875rem;
      cursor: pointer;
      transition: var(--transition);
    }

    .btn:hover {
      border-color: var(--purple);
      background: rgba(181, 123, 238, 0.08);
    }

    .btn-primary {
      background: var(--purple-dim);
      border-color: var(--purple-dim);
      color: white;
    }

    .btn-primary:hover {
      background: var(--purple);
      border-color: var(--purple);
    }

    .quiz-score {
      text-align: center;
      padding: 60px 0;
      display: none;
    }

    .quiz-score.visible {
      display: block;
      animation: fadeIn 0.6s ease;
    }

    .score-number {
      font-family: var(--font-display);
      font-size: 6rem;
      color: var(--purple);
      line-height: 1;
    }

    .score-label {
      font-size: 0.9rem;
      color: var(--text-2);
      margin-top: 8px;
    }

    /* ============================================================
   SECTION 15 — REFERENCES
   ============================================================ */
    #references {
      background: var(--bg-1);
      padding-bottom: 160px;
    }

    .ref-list {
      list-style: none;
      margin-top: 32px;
      display: flex;
      flex-direction: column;
      gap: 10px;
    }

    .ref-list li {
      font-size: 0.82rem;
      color: var(--text-3);
      padding: 10px 0;
      border-bottom: 1px solid var(--border-2);
      display: flex;
      gap: 12px;
    }

    .ref-num {
      color: var(--purple);
      font-family: var(--font-mono);
      flex-shrink: 0;
    }

    .country-note {
      margin-top: 40px;
      padding: 24px 32px;
      background: rgba(77, 208, 225, 0.05);
      border: 1px solid rgba(77, 208, 225, 0.15);
      border-radius: var(--radius);
    }

    .country-note h4 {
      color: var(--teal);
      font-size: 0.85rem;
      margin-bottom: 12px;
      font-family: var(--font-mono);
      letter-spacing: 0.1em;
      text-transform: uppercase;
    }

    .country-note p {
      font-size: 0.82rem;
      color: var(--text-2);
      line-height: 1.7;
    }

    /* ============================================================
   FOOTER
   ============================================================ */
    footer {
      background: var(--bg);
      border-top: 1px solid var(--border);
      padding: 32px 0;
      text-align: center;
    }

    footer p {
      font-size: 0.78rem;
      color: var(--text-3);
      font-family: var(--font-mono);
    }

    /* ============================================================
   KEYBOARD NAV HELPER
   ============================================================ */
    #kbd-hint {
      position: fixed;
      bottom: 24px;
      left: 50%;
      transform: translateX(-50%);
      background: var(--bg-card-2);
      border: 1px solid var(--border);
      border-radius: 100px;
      padding: 10px 20px;
      font-family: var(--font-mono);
      font-size: 11px;
      color: var(--text-3);
      display: flex;
      align-items: center;
      gap: 10px;
      z-index: 500;
      opacity: 1;
      transition: opacity 0.5s;
      pointer-events: none;
    }

    #kbd-hint.hidden {
      opacity: 0;
    }

    kbd {
      background: var(--bg-2);
      border: 1px solid var(--border);
      border-radius: 4px;
      padding: 2px 8px;
      font-size: 11px;
      color: var(--text-2);
    }

    /* ============================================================
   REDUCED MOTION
   ============================================================ */
    @media (prefers-reduced-motion: reduce) {

      *,
      *::before,
      *::after {
        animation-duration: 0.01ms !important;
        transition-duration: 0.01ms !important;
      }
    }

    /* ============================================================
   LARGE SCREEN / PRESENTATION MODE — FONT SCALING
   ============================================================ */
    @media (min-width: 1200px) {
      html {
        font-size: 18px;
      }

      .section-label {
        font-size: 0.8rem;
      }

      .race-bar-label {
        font-size: 0.95rem;
      }

      .stat-label {
        font-size: 0.95rem;
      }

      .figo-type-desc {
        font-size: 0.95rem;
      }

      .figo-type-name {
        font-size: 1rem;
      }

      .diff-feature {
        font-size: 1rem;
      }

      .drug-back li {
        font-size: 0.92rem;
      }

      .drug-warning {
        font-size: 0.88rem;
      }

      .gene-card .gene-desc {
        font-size: 0.95rem;
      }

      .proc-desc {
        font-size: 0.9rem;
      }

      .ref-list li {
        font-size: 0.92rem;
      }

      .pearl-answer {
        font-size: 0.95rem;
      }

      .comp-card {
        font-size: 0.95rem;
      }

      .step-desc {
        font-size: 0.92rem;
      }

      /* Slide counter */
      #slide-counter {
        position: fixed;
        bottom: 24px;
        right: 24px;
        background: var(--bg-card-2);
        border: 1px solid var(--border);
        border-radius: 100px;
        padding: 8px 16px;
        font-family: var(--font-mono);
        font-size: 0.75rem;
        color: var(--text-2);
        z-index: 500;
        letter-spacing: 0.05em;
      }
    }

    /* ============================================================
   COLLAPSIBLE / ACCORDION SYSTEM
   ============================================================ */
    details.collapse-panel {
      border: 1px solid var(--border);
      border-radius: var(--radius-sm);
      margin-bottom: 16px;
      background: var(--bg-card);
      overflow: hidden;
      transition: border-color 0.3s;
    }

    details.collapse-panel[open] {
      border-color: rgba(181, 123, 238, 0.25);
    }

    details.collapse-panel>summary {
      display: flex;
      align-items: center;
      justify-content: space-between;
      padding: 16px 20px;
      cursor: pointer;
      font-family: var(--font-body);
      font-size: 0.95rem;
      font-weight: 600;
      color: var(--text-1);
      list-style: none;
      user-select: none;
      transition: background 0.3s;
    }

    details.collapse-panel>summary:hover {
      background: rgba(181, 123, 238, 0.04);
    }

    details.collapse-panel>summary::-webkit-details-marker {
      display: none;
    }

    details.collapse-panel>summary::after {
      content: '▸';
      font-size: 1rem;
      color: var(--purple);
      transition: transform 0.3s;
      flex-shrink: 0;
      margin-left: 12px;
    }

    details.collapse-panel[open]>summary::after {
      transform: rotate(90deg);
    }

    details.collapse-panel>.collapse-content {
      padding: 16px 24px 24px;
      animation: collapseReveal 0.3s ease-out;
    }

    @keyframes collapseReveal {
      from {
        opacity: 0;
        transform: translateY(-8px);
      }

      to {
        opacity: 1;
        transform: translateY(0);
      }
    }

    details.collapse-panel>summary .collapse-hint {
      font-size: 0.72rem;
      color: var(--text-3);
      font-family: var(--font-mono);
      font-weight: 400;
      letter-spacing: 0.04em;
    }

    details.collapse-panel[open]>summary .collapse-hint {
      display: none;
    }

    /* Minimal variant — no card border, just inline toggle */
    details.collapse-inline {
      margin-bottom: 12px;
    }

    details.collapse-inline>summary {
      display: flex;
      align-items: center;
      gap: 8px;
      cursor: pointer;
      font-size: 0.88rem;
      font-weight: 600;
      color: var(--text-1);
      list-style: none;
      padding: 8px 0;
      border-bottom: 1px solid var(--border-2);
      user-select: none;
    }

    details.collapse-inline>summary::-webkit-details-marker {
      display: none;
    }

    details.collapse-inline>summary::before {
      content: '＋';
      font-size: 0.85rem;
      color: var(--purple);
      font-weight: 700;
      width: 20px;
      text-align: center;
      transition: transform 0.2s;
    }

    details.collapse-inline[open]>summary::before {
      content: '−';
    }

    details.collapse-inline>.collapse-content {
      padding: 12px 0 12px 28px;
      animation: collapseReveal 0.25s ease-out;
    }

    /* India context badge */
    .india-badge {
      display: inline-flex;
      align-items: center;
      gap: 4px;
      background: rgba(255, 183, 77, 0.1);
      border: 1px solid rgba(255, 183, 77, 0.25);
      border-radius: 100px;
      padding: 3px 10px;
      font-size: 0.68rem;
      font-family: var(--font-mono);
      color: var(--amber);
      letter-spacing: 0.05em;
      vertical-align: middle;
    }

    .india-badge.available {
      background: rgba(102, 187, 106, 0.1);
      border-color: rgba(102, 187, 106, 0.25);
      color: var(--green);
    }

    .india-badge.limited {
      background: rgba(255, 183, 77, 0.1);
      border-color: rgba(255, 183, 77, 0.25);
      color: var(--amber);
    }

    .india-badge.unavailable {
      background: rgba(239, 83, 80, 0.1);
      border-color: rgba(239, 83, 80, 0.25);
      color: var(--red);
    }
  </style>
</head>

<body>

  <!-- PROGRESS BAR -->
  <div id="progress-bar"></div>

  <!-- KEYBOARD HINT -->
  <div id="kbd-hint"><kbd>↑</kbd><kbd>↓</kbd> navigate sections <kbd>F</kbd> fullscreen</div>

  <!-- DOT NAVIGATION -->
  <nav id="dot-nav" aria-label="Section navigation">
    <!-- Populated by JS -->
  </nav>

  <!-- SLIDE COUNTER -->
  <div id="slide-counter">1 / 17</div>

  <!-- ============================================================
     SECTION 0 — HERO
     ============================================================ -->
  <section id="hero" aria-label="Title slide">
    <div class="hero-bg">
      <div class="hero-grid"></div>
      <div class="orb orb-1" style="top:-10%;left:-10%;opacity:0.25;"></div>
      <div class="orb orb-2" style="bottom:-15%;right:-5%;opacity:0.18;"></div>
      <div class="orb orb-3" style="top:40%;right:25%;opacity:0.12;"></div>
    </div>

    <!-- Anatomical Uterus SVG -->
    <svg class="uterus-float" viewBox="0 0 340 360" fill="none" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
      <!-- Uterus body -->
      <path
        d="M170 60 C120 60 80 90 70 130 C60 170 65 210 80 240 C95 270 120 290 150 300 C160 304 170 305 170 305 C170 305 180 304 190 300 C220 290 245 270 260 240 C275 210 280 170 270 130 C260 90 220 60 170 60Z"
        fill="rgba(181,123,238,0.08)" stroke="rgba(181,123,238,0.5)" stroke-width="1.5" />
      <!-- Fallopian tubes -->
      <path d="M70 120 C50 110 20 115 10 130 C5 137 8 145 15 148" stroke="rgba(181,123,238,0.5)" stroke-width="1.5"
        fill="none" stroke-linecap="round" />
      <path d="M270 120 C290 110 320 115 330 130 C335 137 332 145 325 148" stroke="rgba(181,123,238,0.5)"
        stroke-width="1.5" fill="none" stroke-linecap="round" />
      <!-- Ovaries -->
      <ellipse cx="12" cy="153" rx="10" ry="7" fill="rgba(240,98,146,0.15)" stroke="rgba(240,98,146,0.5)"
        stroke-width="1.2" />
      <ellipse cx="328" cy="153" rx="10" ry="7" fill="rgba(240,98,146,0.15)" stroke="rgba(240,98,146,0.5)"
        stroke-width="1.2" />
      <!-- Cervix -->
      <path d="M155 305 C155 315 158 330 170 335 C182 330 185 315 185 305" fill="rgba(181,123,238,0.06)"
        stroke="rgba(181,123,238,0.35)" stroke-width="1.2" />
      <!-- Endometrial cavity -->
      <path
        d="M170 100 C155 100 140 120 138 145 C136 170 142 195 155 215 C161 225 170 230 170 230 C170 230 179 225 185 215 C198 195 204 170 202 145 C200 120 185 100 170 100Z"
        fill="rgba(240,98,146,0.1)" stroke="rgba(240,98,146,0.3)" stroke-width="1" />
      <!-- Fibroid representations -->
      <circle cx="125" cy="155" r="22" fill="rgba(181,123,238,0.2)" stroke="rgba(181,123,238,0.7)" stroke-width="1.5"
        stroke-dasharray="4 2" />
      <circle cx="215" cy="175" r="16" fill="rgba(181,123,238,0.15)" stroke="rgba(181,123,238,0.6)" stroke-width="1.2"
        stroke-dasharray="4 2" />
      <circle cx="165" cy="250" r="12" fill="rgba(181,123,238,0.15)" stroke="rgba(181,123,238,0.5)" stroke-width="1"
        stroke-dasharray="3 2" />
      <!-- Labels with leader lines -->
      <line x1="125" y1="133" x2="60" y2="95" stroke="rgba(181,123,238,0.5)" stroke-width="0.8"
        stroke-dasharray="3 2" />
      <text x="5" y="93" font-size="11" fill="rgba(181,123,238,0.9)" font-family="DM Sans, sans-serif"
        font-weight="500">Intramural</text>
      <line x1="215" y1="159" x2="270" y2="125" stroke="rgba(181,123,238,0.5)" stroke-width="0.8"
        stroke-dasharray="3 2" />
      <text x="272" y="123" font-size="11" fill="rgba(181,123,238,0.9)" font-family="DM Sans, sans-serif"
        font-weight="500">Subserosal</text>
      <line x1="165" y1="238" x2="110" y2="280" stroke="rgba(181,123,238,0.5)" stroke-width="0.8"
        stroke-dasharray="3 2" />
      <text x="30" y="285" font-size="11" fill="rgba(240,98,146,0.9)" font-family="DM Sans, sans-serif"
        font-weight="500">Submucosal</text>
      <!-- Anatomical labels -->
      <text x="148" y="55" font-size="9" fill="rgba(255,255,255,0.4)" font-family="DM Mono, monospace"
        text-anchor="middle">FUNDUS</text>
      <text x="148" y="345" font-size="9" fill="rgba(255,255,255,0.4)" font-family="DM Mono, monospace"
        text-anchor="middle">CERVIX</text>
      <text x="12" y="170" font-size="8" fill="rgba(240,98,146,0.5)" font-family="DM Mono, monospace"
        text-anchor="middle">Ovary</text>
      <text x="328" y="170" font-size="8" fill="rgba(240,98,146,0.5)" font-family="DM Mono, monospace"
        text-anchor="middle">Ovary</text>
      <text x="40" y="108" font-size="8" fill="rgba(181,123,238,0.5)" font-family="DM Mono, monospace">Fallopian
        Tube</text>
      <text x="170" y="170" font-size="8" fill="rgba(240,98,146,0.4)" font-family="DM Mono, monospace"
        text-anchor="middle">Endometrium</text>
      <!-- Whorled internal pattern on main fibroid -->
      <circle cx="125" cy="155" r="12" fill="none" stroke="rgba(181,123,238,0.25)" stroke-width="1" />
      <circle cx="125" cy="155" r="6" fill="none" stroke="rgba(181,123,238,0.2)" stroke-width="1" />
    </svg>

    <div class="container">
      <div class="hero-content">
        <div class="hero-eyebrow reveal">OB-GYN · Benign Gynaecology · Medical Lecture</div>
        <h1 class="hero-title reveal">
          <span class="line-1">Uterine</span>
          <span class="line-2">Fibroids</span>
        </h1>
        <p class="hero-subtitle reveal">
          Leiomyomas — the most common benign pelvic tumour in women of reproductive age.
          A comprehensive, clinically-grounded interactive lecture for medical students and educators.
        </p>
        <div class="hero-tags reveal">
          <span class="badge badge-purple">Epidemiology</span>
          <span class="badge badge-pink">Pathophysiology</span>
          <span class="badge badge-teal">FIGO Classification</span>
          <span class="badge badge-amber">Diagnosis</span>
          <span class="badge badge-purple">Management</span>
          <span class="badge badge-red">Emergency</span>
        </div>
        <div class="reveal" style="margin-top:24px;display:flex;align-items:center;gap:16px;">
          <div
            style="width:3px;height:48px;background:linear-gradient(180deg,var(--purple),var(--pink));border-radius:2px;">
          </div>
          <div>
            <p style="font-size:1.05rem;font-weight:600;color:var(--text-1);letter-spacing:0.01em;">Akash Stephen</p>
            <p style="font-size:0.85rem;color:var(--text-2);font-family:var(--font-mono);letter-spacing:0.05em;">Final
              Year MBBS · Dr. SMCSI MCH, Karakonam</p>
          </div>
        </div>
        <div class="hero-stat-row reveal">
          <div class="stat-block">
            <div class="stat-number" data-count="70" data-suffix="%">0%</div>
            <div class="stat-label">of women by age 50</div>
          </div>
          <div class="stat-block">
            <div class="stat-number" data-count="24" data-suffix="–30%">0%</div>
            <div class="stat-label">in Indian women (JOGI)</div>
          </div>
          <div class="stat-block">
            <div class="stat-number" data-count="50" data-suffix="%">0%</div>
            <div class="stat-label">are asymptomatic</div>
          </div>
        </div>
      </div>
    </div>
    <div class="scroll-indicator">
      <span>Scroll</span>
      <div class="scroll-arrow"></div>
    </div>
  </section>

  <!-- ============================================================
     SECTION 1 — EPIDEMIOLOGY
     ============================================================ -->
  <section id="epidemiology" aria-label="Epidemiology">
    <div class="orb orb-1" style="top:20%;right:-10%;opacity:0.15;"></div>
    <div class="container">
      <div class="epi-grid">
        <div>
          <p class="section-label reveal">01 — Epidemiology</p>
          <h2 class="section-title reveal">The <em>Most Common</em> Benign Pelvic Tumour</h2>
          <p class="lead reveal">
            Uterine fibroids (leiomyomas) are benign monoclonal tumours arising from uterine smooth muscle
            cells (myometrium). Their true prevalence is underestimated due to the high rate of asymptomatic cases.
          </p>
          <div class="section-divider"></div>
          <details class="collapse-panel reveal">
            <summary>Indian Prevalence Data <span class="collapse-hint">click to expand</span></summary>
            <div class="collapse-content">
              <div class="race-bar-section">
                <p style="font-size:0.85rem;color:var(--text-2);margin-bottom:20px;line-height:1.7;">
                  Indian studies report a prevalence of <strong style="color:var(--text-1);">24–30%</strong> in
                  reproductive-age women (Gupta et al., JOGI). Peak incidence 30–45 years. High prevalence of
                  <strong style="color:var(--text-1);">vitamin D deficiency</strong> in Indian women is a contributory
                  factor.
                  Iron deficiency anaemia at baseline (NFHS-5: 57% of women aged 15–49) compounds fibroid-related
                  menorrhagia, making earlier intervention more critical.
                </p>
                <div class="race-bar-label"><span>Reproductive age (30–45y)</span><span>24–30%</span></div>
                <div class="race-bar">
                  <div class="race-bar-fill bar-black" data-width="30"></div>
                </div>
                <div class="race-bar-label"><span>Incidental finding (USS)</span><span>~40%</span></div>
                <div class="race-bar">
                  <div class="race-bar-fill bar-white" data-width="40"></div>
                </div>
                <div class="race-bar-label"><span>Hysterectomy specimens</span><span>~77%</span></div>
                <div class="race-bar">
                  <div class="race-bar-fill bar-hisp" data-width="77"></div>
                </div>
                <p style="font-size:0.72rem;color:var(--text-3);margin-top:8px;">Indian data — JOGI, FOGSI guidelines,
                  NFHS-5 (2022)</p>
              </div>

              <!-- FOGSI Note -->
              <div class="card" style="margin-top:20px;border-left:3px solid var(--amber);">
                <div class="section-label" style="color:var(--amber);margin-bottom:8px;">🇮🇳 FOGSI Approach</div>
                <p style="font-size:0.85rem;color:var(--text-2);line-height:1.7;">
                  FOGSI (Federation of Obstetric & Gynaecological Societies of India) guidelines recommend a
                  structured stepwise approach to management — Medical → Interventional → Surgical — considering
                  local drug availability, cost factors, and patient preferences.
                </p>
              </div>
            </div>
          </details>
        </div>
        <div>
          <div class="stat-cards reveal">
            <div class="stat-card">
              <div class="stat-number" data-count="25" data-suffix="%">0%</div>
              <div class="stat-label">clinically symptomatic</div>
            </div>
            <div class="stat-card">
              <div class="stat-number" data-count="77" data-suffix="%">0%</div>
              <div class="stat-label">in hysterectomy specimens (India)</div>
            </div>
            <div class="stat-card">
              <div class="stat-number">Peak</div>
              <div class="stat-label">30–40 years (reproductive age)</div>
            </div>
            <div class="stat-card">
              <div class="stat-number">Rare</div>
              <div class="stat-label">post-menopausal (regression)</div>
            </div>
          </div>
          <details class="collapse-panel reveal">
            <summary>Risk Factors (↑ and ↓) <span class="collapse-hint">click to expand</span></summary>
            <div class="collapse-content">
              <div style="display:grid;grid-template-columns:1fr 1fr;gap:10px;">
                <div>
                  <p style="font-size:0.78rem;color:var(--purple);font-family:var(--font-mono);margin-bottom:8px;">↑
                    Risk
                  </p>
                  <ul style="list-style:none;font-size:0.8rem;color:var(--text-2);">
                    <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Vitamin D deficiency (highly
                      prevalent in India)</li>
                    <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Early menarche (&lt;10 years)
                    </li>
                    <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Nulliparity</li>
                    <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Obesity (↑ peripheral oestrogen)
                    </li>
                    <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Family history (first-degree)
                    </li>
                    <li style="padding:4px 0;">Hypertension</li>
                  </ul>
                </div>
                <div>
                  <p style="font-size:0.78rem;color:var(--green);font-family:var(--font-mono);margin-bottom:8px;">↓ Risk
                  </p>
                  <ul style="list-style:none;font-size:0.8rem;color:var(--text-2);">
                    <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Multiparity (each pregnancy ↓
                      risk
                      ~20%)</li>
                    <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Late menarche</li>
                    <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Cigarette smoking
                      (epidemiologically associated — weak anti-oestrogenic effect via AhR pathway; <em>not a clinical
                        recommendation</em>)</li>
                    <li style="padding:4px 0;">Prolonged OCP use</li>
                  </ul>
                </div>
              </div>
            </div>
          </details>
        </div>
      </div>
    </div>
  </section>

  <!-- ============================================================
     SECTION 2 — PATHOPHYSIOLOGY
     ============================================================ -->
  <section id="pathophysiology" aria-label="Pathophysiology">
    <div class="orb orb-2" style="bottom:-10%;left:-5%;opacity:0.12;"></div>
    <div class="container">
      <p class="section-label reveal">02 — Pathophysiology</p>
      <h2 class="section-title reveal">Hormonal & <em>Genetic</em> Drivers</h2>
      <p class="lead reveal">
        Fibroids are monoclonal in origin — each tumour arises from a single myometrial smooth muscle cell. Their growth
        is primarily driven by oestrogen and progesterone, with critical roles for somatic genetic mutations and
        extracellular matrix dysregulation.
      </p>

      <details class="collapse-panel reveal">
        <summary>Pathogenesis Pathway: Mutation → Leiomyoma <span class="collapse-hint">click to expand</span></summary>
        <div class="collapse-content">
          <div class="pathway-flow" style="margin:16px 0;">
            <div class="pathway-node">
              <div class="node-icon">🧬</div>
              <h4>Somatic Mutation</h4>
              <p>MED12, HMGA2, FH, COL4A5/A6</p>
            </div>
            <div class="pathway-arrow">→</div>
            <div class="pathway-node">
              <div class="node-icon">🔴</div>
              <h4>Myometrial Stem Cell</h4>
              <p>Clonal transformation</p>
            </div>
            <div class="pathway-arrow">→</div>
            <div class="pathway-node">
              <div class="node-icon">🔄</div>
              <h4>Hormonal Stimulation</h4>
              <p>Oestrogen + Progesterone</p>
            </div>
            <div class="pathway-arrow">→</div>
            <div class="pathway-node">
              <div class="node-icon">⬆️</div>
              <h4>Growth Factor ↑</h4>
              <p>IGF-1, EGF, TGF-β, VEGF</p>
            </div>
            <div class="pathway-arrow">→</div>
            <div class="pathway-node">
              <div class="node-icon">🟣</div>
              <h4>ECM Accumulation</h4>
              <p>Collagen, fibronectin, proteoglycan</p>
            </div>
            <div class="pathway-arrow">→</div>
            <div class="pathway-node">
              <div class="node-icon">🟣</div>
              <h4>Leiomyoma</h4>
              <p>Whorled, well-circumscribed mass</p>
            </div>
          </div>
        </div>
      </details>

      <details class="collapse-panel reveal">
        <summary>Hormonal Dependency — Oestrogen, Progesterone & Vasculature <span class="collapse-hint">click to
            expand</span></summary>
        <div class="collapse-content">
          <div style="display:grid;grid-template-columns:1fr 1fr 1fr;gap:24px;">
            <div>
              <p
                style="color:var(--pink);font-family:var(--font-mono);font-size:11px;letter-spacing:0.1em;text-transform:uppercase;margin-bottom:10px;">
                Oestrogen</p>
              <ul style="list-style:none;font-size:0.82rem;color:var(--text-2);">
                <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">↑ ERα and ERβ expression in fibroid
                  tissue vs normal myometrium</li>
                <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Promotes growth factor (IGF-1, EGF)
                  secretion</li>
                <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Explains absence before menarche and
                  regression post-menopause</li>
              </ul>
            </div>
            <div>
              <p
                style="color:var(--purple);font-family:var(--font-mono);font-size:11px;letter-spacing:0.1em;text-transform:uppercase;margin-bottom:10px;">
                Progesterone</p>
              <ul style="list-style:none;font-size:0.82rem;color:var(--text-2);">
                <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Acts synergistically with oestrogen —
                  critical for growth (not oestrogen alone)</li>
                <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Promotes cell proliferation and
                  inhibits apoptosis</li>
                <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Target of SPRMs (selective
                  progesterone
                  receptor modulators)</li>
              </ul>
            </div>
            <div>
              <p
                style="color:var(--teal);font-family:var(--font-mono);font-size:11px;letter-spacing:0.1em;text-transform:uppercase;margin-bottom:10px;">
                Vasculature</p>
              <ul style="list-style:none;font-size:0.82rem;color:var(--text-2);">
                <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Fibroids have abnormal vasculature
                  with
                  aberrant arteries</li>
                <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Submucosal type disrupts spiral
                  arteriole remodelling → AUB</li>
                <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">VEGF over-expression → basis of UAE
                  treatment</li>
              </ul>
            </div>
          </div>
        </div>
      </details>

      <details class="collapse-panel reveal">
        <summary>Genetic Mutations — MED12, HMGA2, FH, COL4A5/6 <span class="collapse-hint">click to expand</span>
        </summary>
        <div class="collapse-content">
          <div class="gene-cards">
            <div class="gene-card">
              <div class="gene-name">MED12</div>
              <div class="gene-freq">~70%</div>
              <p style="font-size:0.78rem;color:var(--text-2);">Most frequent somatic mutation; exon 2 hotspot. Mediator
                complex subunit — regulates transcription. Loss of function = dysregulated cell growth.</p>
            </div>
            <div class="gene-card">
              <div class="gene-name">HMGA2</div>
              <div class="gene-freq">~20%</div>
              <p style="font-size:0.78rem;color:var(--text-2);">High mobility group AT-hook 2. Rearrangements at
                12q14-15.
                Promotes IGF2BP2 — associated with larger fibroids.</p>
            </div>
            <div class="gene-card">
              <div class="gene-name">FH</div>
              <div class="gene-freq">Rare</div>
              <p style="font-size:0.78rem;color:var(--text-2);">Fumarate hydratase (Krebs cycle). Germline mutation →
                <strong style="color:var(--amber);">HLRCC</strong> — hereditary leiomyomatosis & renal cell carcinoma.
                High-yield: aggressive fibroids in young women.
              </p>
            </div>
            <div class="gene-card">
              <div class="gene-name">COL4A5/6</div>
              <div class="gene-freq">~4%</div>
              <p style="font-size:0.78rem;color:var(--text-2);">Collagen type IV deletion at Xq22.3. Associated with
                large
                exophytic fibroids. ECM-driven pathogenesis.</p>
            </div>
          </div>
        </div>
      </details>

      <details class="collapse-panel reveal">
        <summary>Gross & Microscopic Pathology + Degeneration Types <span class="collapse-hint">click to expand</span>
        </summary>
        <div class="collapse-content">
          <div style="display:grid;grid-template-columns:1fr 1fr;gap:32px;">
            <div>
              <p style="color:var(--text-1);font-weight:600;margin-bottom:8px;">Macroscopic</p>
              <ul style="list-style:none;font-size:0.82rem;color:var(--text-2);">
                <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Well-circumscribed,
                  pseudo-encapsulated
                  (not a true capsule)</li>
                <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Firm, rubbery texture; whorled pale
                  cut
                  surface</li>
                <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Size: mm to &gt;30 cm (record: 45 kg
                  removed)</li>
                <li style="padding:4px 0;">Solitary or multiple (70% of cases); average 6–7 fibroids if multiple</li>
              </ul>
            </div>
            <div>
              <p style="color:var(--text-1);font-weight:600;margin-bottom:8px;">Microscopic</p>
              <ul style="list-style:none;font-size:0.82rem;color:var(--text-2);">
                <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Whorled bundles of smooth muscle
                  cells
                  — uniform, cigar-shaped nuclei</li>
                <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Abundant collagen ECM between muscle
                  bundles</li>
                <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">No mitoses (<5 mitoses/10 HPF), no
                    nuclear atypia (contrast with leiomyosarcoma)</li>
                <li style="padding:4px 0;">Variants: cellular, bizarre (symplastic), mitotically active — all benign
                </li>
              </ul>
            </div>
          </div>
          <div
            style="margin-top:20px;padding:16px 20px;background:rgba(255,183,77,0.06);border:1px solid rgba(255,183,77,0.2);border-radius:var(--radius-sm);">
            <p style="font-size:0.82rem;color:var(--amber);"><strong>Degeneration types (when fibroid outgrows blood
                supply):</strong> Hyaline (most common, 65%) → Cystic → Calcification (post-menopausal) →
              <strong>Red/Carneous</strong> (pregnancy — acute haemorrhagic infarction) → Myxoid
            </p>
            <p style="font-size:0.78rem;color:var(--text-2);margin-top:8px;"><strong style="color:var(--red);">⚠
                Note:</strong> Leiomyosarcoma (LMS) is a <em>de novo</em> malignancy — it does <strong>not</strong>
              arise
              from malignant transformation of benign fibroids. Do not confuse with degeneration.</p>
          </div>
        </div>
      </details>
    </div>
  </section>

  <!-- ============================================================
     SECTION 3 — CLASSIFICATION BY LOCATION
     ============================================================ -->
  <section id="classification" aria-label="Classification by location">
    <div class="container">
      <p class="section-label reveal">03 — Classification</p>
      <h2 class="section-title reveal">Types by <em>Location</em></h2>
      <p class="lead reveal">The anatomical location of a fibroid is the primary determinant of its clinical
        presentation. The same size fibroid can cause dramatically different symptoms depending on its relationship to
        the endometrial cavity and uterine serosa.</p>

      <div class="fibroid-explorer" style="margin-top:48px;">
        <div class="type-tabs reveal" id="typeTabs">
          <div class="type-tab active" data-type="intramural">
            <div style="display:flex;align-items:center;gap:12px;margin-bottom:6px;">
              <span class="badge badge-purple">Most Common</span>
            </div>
            <h4>Intramural (IM)</h4>
            <p>Within the myometrial wall, fully contained. ~70% of all fibroids.</p>
          </div>
          <div class="type-tab" data-type="submucosal">
            <div style="display:flex;align-items:center;gap:12px;margin-bottom:6px;">
              <span class="badge badge-pink">Most Symptomatic</span>
            </div>
            <h4>Submucosal (SM)</h4>
            <p>Distorts endometrial cavity. FIGO Types 0–3. Critical for AUB and infertility.</p>
          </div>
          <div class="type-tab" data-type="subserosal">
            <div style="display:flex;align-items:center;gap:12px;margin-bottom:6px;">
              <span class="badge badge-teal">Bulk Symptoms</span>
            </div>
            <h4>Subserosal (SS)</h4>
            <p>Projects from uterine surface outward. Causes pelvic pressure, urinary frequency.</p>
          </div>
          <div class="type-tab" data-type="pedunculated">
            <div style="display:flex;align-items:center;gap:12px;margin-bottom:6px;">
              <span class="badge badge-amber">Torsion Risk</span>
            </div>
            <h4>Pedunculated</h4>
            <p>Attached by a stalk — can be intracavitary (SM) or extracavitary (SS). Risk of torsion.</p>
          </div>
          <div class="type-tab" data-type="cervical">
            <div style="display:flex;align-items:center;gap:12px;margin-bottom:6px;">
              <span class="badge badge-red">FIGO Type 8</span>
            </div>
            <h4>Cervical / Parasitic</h4>
            <p>In cervical stroma or attached to other pelvic organs. Rare. FIGO Type 8 — "Other".</p>
          </div>
        </div>

        <div class="type-detail-panel reveal" id="typeDetailPanel">
          <!-- Uterus SVG for classification -->
          <svg class="uterus-diagram" viewBox="0 0 300 320" fill="none" xmlns="http://www.w3.org/2000/svg"
            id="classificationSvg">
            <defs>
              <filter id="glow">
                <feGaussianBlur stdDeviation="4" result="blur" />
                <feMerge>
                  <feMergeNode in="blur" />
                  <feMergeNode in="SourceGraphic" />
                </feMerge>
              </filter>
            </defs>
            <!-- Uterus -->
            <path
              d="M150 45 C108 45 75 72 66 108 C57 145 62 180 75 208 C88 236 112 254 138 263 C145 266 150 267 150 267 C150 267 155 266 162 263 C188 254 212 236 225 208 C238 180 243 145 234 108 C225 72 192 45 150 45Z"
              fill="rgba(181,123,238,0.07)" stroke="rgba(181,123,238,0.4)" stroke-width="1.5" />
            <!-- Fallopian tubes -->
            <path d="M66 102 C48 93 22 97 12 110 C8 116 10 122 16 125" stroke="rgba(181,123,238,0.4)" stroke-width="1.3"
              fill="none" stroke-linecap="round" />
            <path d="M234 102 C252 93 278 97 288 110 C292 116 290 122 284 125" stroke="rgba(181,123,238,0.4)"
              stroke-width="1.3" fill="none" stroke-linecap="round" />
            <!-- Ovaries -->
            <ellipse cx="11" cy="129" rx="9" ry="6" fill="rgba(240,98,146,0.12)" stroke="rgba(240,98,146,0.4)"
              stroke-width="1" />
            <ellipse cx="289" cy="129" rx="9" ry="6" fill="rgba(240,98,146,0.12)" stroke="rgba(240,98,146,0.4)"
              stroke-width="1" />
            <!-- Endometrial cavity -->
            <path
              d="M150 85 C138 85 125 102 123 125 C121 148 127 170 138 186 C143 194 150 198 150 198 C150 198 157 194 162 186 C173 170 179 148 177 125 C175 102 162 85 150 85Z"
              fill="rgba(240,98,146,0.08)" stroke="rgba(240,98,146,0.25)" stroke-width="1" />
            <!-- Cervix -->
            <path d="M138 267 C138 276 141 290 150 295 C159 290 162 276 162 267" fill="rgba(181,123,238,0.05)"
              stroke="rgba(181,123,238,0.3)" stroke-width="1" />
            <!-- Fibroids (toggled by JS) -->
            <!-- Intramural -->
            <circle id="fib-im-1" cx="108" cy="148" r="24" fill="rgba(181,123,238,0.25)" stroke="#b57bee"
              stroke-width="2" stroke-dasharray="5 2" />
            <circle id="fib-im-2" cx="195" cy="165" r="17" fill="rgba(181,123,238,0.2)" stroke="#b57bee"
              stroke-width="1.5" stroke-dasharray="4 2" />
            <!-- Submucosal -->
            <circle id="fib-sm-1" cx="140" cy="130" r="18" fill="rgba(240,98,146,0.3)" stroke="#f06292" stroke-width="2"
              stroke-dasharray="5 2" style="display:none" />
            <!-- Subserosal -->
            <circle id="fib-ss-1" cx="235" cy="130" r="22" fill="rgba(77,208,225,0.25)" stroke="#4dd0e1"
              stroke-width="2" stroke-dasharray="5 2" style="display:none" />
            <!-- Pedunculated subserosal on stalk -->
            <line id="fib-ped-stalk" x1="240" y1="145" x2="265" y2="110" stroke="#ffb74d" stroke-width="1.5"
              style="display:none" />
            <circle id="fib-ped-1" cx="272" cy="100" r="20" fill="rgba(255,183,77,0.25)" stroke="#ffb74d"
              stroke-width="2" stroke-dasharray="5 2" style="display:none" />
            <!-- Cervical -->
            <circle id="fib-cerv-1" cx="150" cy="285" r="15" fill="rgba(239,83,80,0.25)" stroke="#ef5350"
              stroke-width="2" stroke-dasharray="4 2" style="display:none" />
            <!-- Anatomical labels -->
            <text x="150" y="38" font-size="9" fill="rgba(255,255,255,0.45)" font-family="DM Mono, monospace"
              text-anchor="middle">FUNDUS</text>
            <text x="150" y="310" font-size="9" fill="rgba(255,255,255,0.45)" font-family="DM Mono, monospace"
              text-anchor="middle">CERVIX</text>
            <text x="80" y="210" font-size="8" fill="rgba(181,123,238,0.45)"
              font-family="DM Mono, monospace">Myometrium</text>
            <text x="150" y="145" font-size="8" fill="rgba(240,98,146,0.45)" font-family="DM Mono, monospace"
              text-anchor="middle">Endometrium</text>
          </svg>

          <div id="typeDetail">
            <div class="detail-tag"><span class="badge badge-purple">Intramural</span></div>
            <div class="detail-title">Intramural Fibroid</div>
            <div class="detail-body">
              Entirely within the myometrium, not distorting the endometrial cavity or serosal surface. The most common
              type (~70%). May enlarge significantly before becoming symptomatic.
            </div>
            <ul class="detail-list">
              <li>Menorrhagia if large enough to disrupt endometrial vascular remodelling</li>
              <li>Pelvic heaviness and dysmenorrhoea with large fibroids</li>
              <li>Subfertility if cavity significantly distorted (FIGO Type 3)</li>
              <li>Irregular, non-tender uterine enlargement on examination</li>
              <li>Management: medical first-line; myomectomy (lap/open) or UAE if symptomatic</li>
            </ul>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- ============================================================
     SECTION 4 — FIGO CLASSIFICATION
     ============================================================ -->
  <section id="figo" aria-label="FIGO classification">
    <div class="orb orb-3" style="top:10%;right:5%;opacity:0.1;"></div>
    <div class="container">
      <p class="section-label reveal">04 — FIGO Classification</p>
      <h2 class="section-title reveal">Leiomyoma <em>Subclassification</em></h2>
      <p class="lead reveal">
        The FIGO leiomyoma subclassification system (Munro et al. 2011, updated 2018) defines 9 types (0–8) based on the
        fibroid's relationship to the endometrial cavity, myometrium, and serosal surface. Types 0–3 are submucosal;
        Types 4–6 are intramural/subserosal; Types 7–8 are special categories.
      </p>
      <div
        style="margin-top:16px;padding:16px 24px;background:rgba(77,208,225,0.06);border:1px solid rgba(77,208,225,0.2);border-radius:var(--radius-sm);display:inline-block;">
        <p style="font-size:0.82rem;color:var(--teal);">📌 The FIGO system is used within the
          <strong>PALM-COEIN</strong> classification of Abnormal Uterine Bleeding — the "L" in PALM = Leiomyoma,
          specified using this subclassification.
        </p>
      </div>
      <div class="figo-grid reveal">
        <div class="figo-card active" data-figo="0">
          <div class="figo-number">0</div>
          <div class="figo-name">Pedunculated Intracavitary</div>
          <div class="figo-desc">Entirely within the cavity on a stalk. No intramural component. Hysteroscopic resection
            possible.</div>
          <div class="figo-location"><span class="badge badge-pink">Submucosal</span></div>
        </div>
        <div class="figo-card" data-figo="1">
          <div class="figo-number">1</div>
          <div class="figo-name">&lt;50% Intramural</div>
          <div class="figo-desc">Submucosal; less than 50% of the fibroid diameter is within the myometrium.
            Hysteroscopic resection (often 2-stage for larger lesions).</div>
          <div class="figo-location"><span class="badge badge-pink">Submucosal</span></div>
        </div>
        <div class="figo-card" data-figo="2">
          <div class="figo-number">2</div>
          <div class="figo-name">≥50% Intramural</div>
          <div class="figo-desc">Submucosal; at least 50% is within the myometrium. More difficult hysteroscopic
            resection — may require 2-stage approach or laparoscopic myomectomy.</div>
          <div class="figo-location"><span class="badge badge-pink">Submucosal</span></div>
        </div>
        <div class="figo-card" data-figo="3">
          <div class="figo-number">3</div>
          <div class="figo-name">Contacts Endometrium</div>
          <div class="figo-desc">100% intramural but contacts the endometrium. Cavity not visually distorted on
            hysteroscopy, but can impact implantation. FIGO 2018 addition.</div>
          <div class="figo-location"><span class="badge badge-purple">Intramural</span></div>
        </div>
        <div class="figo-card" data-figo="4">
          <div class="figo-number">4</div>
          <div class="figo-name">Intramural</div>
          <div class="figo-desc">Entirely within the myometrium. Does not contact endometrium or serosa. Most common
            histological type.</div>
          <div class="figo-location"><span class="badge badge-purple">Intramural</span></div>
        </div>
        <div class="figo-card" data-figo="5">
          <div class="figo-number">5</div>
          <div class="figo-name">Subserosal ≥50% IM</div>
          <div class="figo-desc">Subserosal with at least 50% of its diameter within the myometrium.</div>
          <div class="figo-location"><span class="badge badge-teal">Subserosal</span></div>
        </div>
        <div class="figo-card" data-figo="6">
          <div class="figo-number">6</div>
          <div class="figo-name">Subserosal &lt;50% IM</div>
          <div class="figo-desc">Predominantly exophytic — less than 50% within myometrium. Causes bulk symptoms.</div>
          <div class="figo-location"><span class="badge badge-teal">Subserosal</span></div>
        </div>
        <div class="figo-card" data-figo="7">
          <div class="figo-number">7</div>
          <div class="figo-name">Pedunculated Subserosal</div>
          <div class="figo-desc">Attached to uterine surface by a stalk. Risk of torsion → acute pelvic pain. Can be
            confused with ovarian mass on imaging.</div>
          <div class="figo-location"><span class="badge badge-amber">Pedunculated</span></div>
        </div>
        <div class="figo-card" data-figo="8">
          <div class="figo-number">8</div>
          <div class="figo-name">Other / Special</div>
          <div class="figo-desc">Cervical, broad ligament, or parasitic fibroids (detached from uterus, blood supply
            from other structures). Cannot be classified 0–7.</div>
          <div class="figo-location"><span class="badge badge-red">Special</span></div>
        </div>
      </div>
      <div class="card reveal" style="margin-top:24px;">
        <p style="font-size:0.85rem;color:var(--text-2);line-height:1.8;">
          <strong style="color:var(--purple);">Hybrid notation:</strong> When a fibroid spans two categories, a
          two-number designation is used (e.g., "2–5" = submucosal, ≥50% intramural, with subserosal extension). This is
          important for pre-operative planning and predicting hysteroscopic difficulty (ESGE Difficulty Score also uses
          FIGO type).
        </p>
      </div>
    </div>
  </section>

  <!-- ============================================================
     SECTION 5 — SYMPTOMS
     ============================================================ -->
  <section id="symptoms" aria-label="Symptoms and clinical features">
    <div class="container">
      <p class="section-label reveal">05 — Symptoms</p>
      <h2 class="section-title reveal">Clinical <em>Presentation</em></h2>
      <p class="lead reveal">Symptoms depend on fibroid size, number, and most importantly, location. Up to 50% of
        fibroids are asymptomatic and discovered incidentally on imaging or examination.</p>

      <details class="collapse-panel reveal">
        <summary>Symptom Categories — AUB, Bulk, Pain, Reproductive <span class="collapse-hint">click to expand</span>
        </summary>
        <div class="collapse-content">
          <div class="symptom-categories">
            <div>
              <div class="symptom-cat-title">Abnormal Uterine Bleeding (AUB)</div>
              <div class="symptom-item">
                <div class="severity-dot sev-high"></div>
                <div class="symptom-icon">🩸</div>
                <div class="symptom-text">
                  <h5>Menorrhagia (Heavy Menstrual Bleeding)</h5>
                  <p>Most common symptom. Defined as ≥80 mL/cycle. Submucosal fibroids predominate — disrupt endometrial
                    spiral arteriole remodelling, impair haemostasis (altered coagulation factors locally), and increase
                    endometrial surface area. Can cause iron deficiency anaemia.</p>
                </div>
              </div>
              <div class="symptom-item">
                <div class="severity-dot sev-med"></div>
                <div class="symptom-icon">📅</div>
                <div class="symptom-text">
                  <h5>Dysmenorrhoea</h5>
                  <p>Particularly with submucosal fibroids. Uterine cramping as fibroid distorts cavity. Also:
                    intermenstrual bleeding (polymenorrhagia) with pedunculated intracavitary types.</p>
                </div>
              </div>
              <div class="symptom-item">
                <div class="severity-dot sev-low"></div>
                <div class="symptom-icon">🔴</div>
                <div class="symptom-text">
                  <h5>Post-coital Bleeding</h5>
                  <p>Less common; may occur with cervical or prolapsed submucosal fibroids.</p>
                </div>
              </div>
            </div>
            <div>
              <div class="symptom-cat-title">Bulk / Pressure Symptoms</div>
              <div class="symptom-item">
                <div class="severity-dot sev-high"></div>
                <div class="symptom-icon">💧</div>
                <div class="symptom-text">
                  <h5>Urinary Symptoms</h5>
                  <p>Frequency and urgency from anterior fibroid compressing bladder. Hydronephrosis (rare) from lateral
                    compression of ureter. Urinary retention from large cervical fibroid (rare but high-yield).</p>
                </div>
              </div>
              <div class="symptom-item">
                <div class="severity-dot sev-med"></div>
                <div class="symptom-icon">🔵</div>
                <div class="symptom-text">
                  <h5>Pelvic Pressure / Heaviness</h5>
                  <p>Particularly with large intramural or subserosal fibroids. Feeling of "fullness" in lower abdomen.
                  </p>
                </div>
              </div>
              <div class="symptom-item">
                <div class="severity-dot sev-low"></div>
                <div class="symptom-icon">💩</div>
                <div class="symptom-text">
                  <h5>Bowel Symptoms</h5>
                  <p>Constipation or tenesmus from posterior fibroid pressing on rectosigmoid.</p>
                </div>
              </div>
            </div>
            <div>
              <div class="symptom-cat-title">Pain</div>
              <div class="symptom-item">
                <div class="severity-dot sev-high"></div>
                <div class="symptom-icon">⚡</div>
                <div class="symptom-text">
                  <h5>Acute Pelvic Pain</h5>
                  <p>Red degeneration (pregnancy), torsion (pedunculated), or acute haemorrhage within a fibroid. May
                    mimic
                    appendicitis or ovarian torsion.</p>
                </div>
              </div>
              <div class="symptom-item">
                <div class="severity-dot sev-med"></div>
                <div class="symptom-icon">😣</div>
                <div class="symptom-text">
                  <h5>Dyspareunia</h5>
                  <p>Deep dyspareunia from posterior intramural or broad ligament fibroids. Prolapsed pedunculated
                    fibroid
                    through cervix → apareunia.</p>
                </div>
              </div>
            </div>
            <div>
              <div class="symptom-cat-title">Reproductive</div>
              <div class="symptom-item">
                <div class="severity-dot sev-high"></div>
                <div class="symptom-icon">🤰</div>
                <div class="symptom-text">
                  <h5>Infertility</h5>
                  <p>Submucosal fibroids (especially Types 0–2) are most clearly associated. Mechanisms: impaired sperm
                    transport, embryo implantation failure, altered endometrial receptivity (HOXA10, HOXA11
                    suppression),
                    disrupted uterine contractility.</p>
                </div>
              </div>
              <div class="symptom-item">
                <div class="severity-dot sev-med"></div>
                <div class="symptom-icon">💔</div>
                <div class="symptom-text">
                  <h5>Recurrent Pregnancy Loss</h5>
                  <p>Cavity-distorting fibroids. Mechanical obstruction of embryo implantation site, abnormal
                    endometrial
                    vascularity, elevated uterine contractility.</p>
                </div>
              </div>
            </div>
          </div>

        </div>
      </details>

      <details class="collapse-panel reveal">
        <summary>50% Asymptomatic — Key Incidental Finding <span class="collapse-hint">click to expand</span></summary>
        <div class="collapse-content">
          <div class="asymptomatic-callout">
            <div class="callout-big">50%</div>
            <div>
              <p style="font-size:0.9rem;font-weight:600;margin-bottom:6px;">Asymptomatic — Incidental Finding</p>
              <p style="font-size:0.83rem;color:var(--text-2);line-height:1.7;">Approximately 50% of women with fibroids
                have no symptoms. Discovery is often incidental during pelvic ultrasound for another indication, or on
                bimanual examination. Asymptomatic fibroids do not require treatment — only surveillance.</p>
            </div>
          </div>
        </div>
      </details>

      <details class="collapse-panel reveal">
        <summary>Clinical Examination Findings <span class="collapse-hint">click to expand</span></summary>
        <div class="collapse-content">
          <div style="display:grid;grid-template-columns:1fr 1fr;gap:24px;font-size:0.85rem;color:var(--text-2);">
            <div>
              <ul style="list-style:none;">
                <li style="padding:6px 0;border-bottom:1px solid var(--border-2);display:flex;gap:10px;"><span
                    style="color:var(--purple);">→</span> Enlarged uterus on abdominal examination (may be visible as
                  suprapubic mass if large)</li>
                <li style="padding:6px 0;border-bottom:1px solid var(--border-2);display:flex;gap:10px;"><span
                    style="color:var(--purple);">→</span> Bimanual: enlarged, <strong
                    style="color:var(--text-1);">irregular</strong>, firm, <strong
                    style="color:var(--text-1);">non-tender</strong> uterus (tenderness suggests degeneration/torsion)
                </li>
                <li style="padding:6px 0;display:flex;gap:10px;"><span style="color:var(--purple);">→</span> Mobile
                  uterus
                  (adhesions suggest endometriosis or PID)</li>
              </ul>
            </div>
            <div>
              <ul style="list-style:none;">
                <li style="padding:6px 0;border-bottom:1px solid var(--border-2);display:flex;gap:10px;"><span
                    style="color:var(--purple);">→</span> Speculum: cervix may appear deviated; prolapsed pedunculated
                  fibroid visible</li>
                <li style="padding:6px 0;border-bottom:1px solid var(--border-2);display:flex;gap:10px;"><span
                    style="color:var(--purple);">→</span> Signs of anaemia: pallor of conjunctivae, tachycardia</li>
                <li style="padding:6px 0;display:flex;gap:10px;"><span style="color:var(--purple);">→</span> Note:
                  uterine
                  size classically described in obstetric weeks (e.g., "16-week size uterus")</li>
              </ul>
            </div>
          </div>
        </div>
      </details>
    </div>
  </section>

  <!-- ============================================================
     SECTION 6 — COMPLICATIONS
     ============================================================ -->
  <section id="complications" aria-label="Complications">
    <div class="orb orb-1" style="bottom:-10%;right:-5%;opacity:0.1;"></div>
    <div class="container">
      <p class="section-label reveal">06 — Complications</p>
      <h2 class="section-title reveal">Clinical <em>Complications</em></h2>
      <p class="lead reveal">Fibroids can cause significant morbidity through multiple mechanisms — haematological,
        reproductive, obstetric, and rarely acute surgical emergencies.</p>

      <details class="collapse-panel reveal">
        <summary>Complication Cards — Haematological, Obstetric, Acute, Fertility, Surgical, Malignancy <span
            class="collapse-hint">click to expand</span></summary>
        <div class="collapse-content">
          <div class="complication-cards">
            <div class="comp-card">
              <div class="comp-icon">🩸</div>
              <div class="comp-title">Haematological</div>
              <ul class="comp-items">
                <li>Iron deficiency anaemia — chronic blood loss from menorrhagia; Hb may drop to &lt;8 g/dL in severe
                  cases
                </li>
                <li>Pre-operative anaemia increases surgical risk — GnRH agonists or tranexamic acid used to restore Hb
                  before surgery</li>
                <li>Acute haemorrhage — rare but life-threatening; may require emergency intervention</li>
                <li>Venous thromboembolism (VTE) — large fibroids causing pelvic venous stasis (rare)</li>
              </ul>
            </div>
            <div class="comp-card">
              <div class="comp-icon">🤰</div>
              <div class="comp-title">Obstetric</div>
              <ul class="comp-items">
                <li>Preterm labour and delivery (especially submucosal)</li>
                <li>Malpresentation — large fibroids distort uterine shape, preventing cephalic presentation</li>
                <li>Placenta praevia — fibroid occupies lower segment</li>
                <li>Placental abruption (fibroid behind placenta)</li>
                <li>Uterine rupture (rare, posterior fibroid weakening)</li>
                <li>Post-partum haemorrhage (PPH) — impaired uterine contractility</li>
                <li>Increased caesarean section rate (Caesarean myomectomy now often performed in select cases — FOGSI)
                </li>
                <li>First trimester miscarriage ↑ risk (submucous)</li>
              </ul>
            </div>
            <div class="comp-card">
              <div class="comp-icon">⚡</div>
              <div class="comp-title">Acute / Structural</div>
              <ul class="comp-items">
                <li><strong>Red/Carneous degeneration</strong> — acute infarction in pregnancy; severe localised pain,
                  low-grade fever, leucocytosis; self-limiting (managed conservatively)</li>
                <li><strong>Torsion</strong> — pedunculated fibroid on stalk twists; acute abdomen; surgical emergency
                </li>
                <li>Urinary retention — large cervical fibroid compresses urethra</li>
                <li>Hydronephrosis — lateral compression of ureter (rare, chronic)</li>
                <li>Prolapse of pedunculated submucosal fibroid through os — visualised on speculum</li>
              </ul>
            </div>
            <div class="comp-card">
              <div class="comp-icon">🔬</div>
              <div class="comp-title">Infertility &amp; IVF</div>
              <ul class="comp-items">
                <li>Submucosal fibroids significantly ↓ IVF success rates (RR ~0.3 for live birth)</li>
                <li>Even FIGO Type 3 (contacts but doesn't distort endometrium) may impair implantation</li>
                <li>Intramural fibroids ≥4–5 cm — may reduce IVF success (controversial, guideline-dependent)</li>
                <li>Myomectomy before IVF for symptomatic submucosal fibroids is recommended</li>
                <li>Recurrent implantation failure — consider hysteroscopy to exclude cavity pathology</li>
              </ul>
            </div>
            <div class="comp-card">
              <div class="comp-icon">⚙️</div>
              <div class="comp-title">Surgical Complications</div>
              <ul class="comp-items">
                <li>Myomectomy → risk of conversion to hysterectomy (0.1–1%)</li>
                <li>Uterine rupture in subsequent pregnancy after myomectomy (especially open)</li>
                <li>UAE → post-embolisation syndrome (fever, pain, malaise); amenorrhoea risk (1–2%)</li>
                <li>Morcellation concerns — if occult LMS: risk of dissemination (FDA black box warning 2014)</li>
              </ul>
            </div>
            <div class="comp-card">
              <div class="comp-icon">🔴</div>
              <div class="comp-title">Malignancy Question</div>
              <ul class="comp-items">
                <li>Leiomyosarcoma (LMS) does NOT arise from malignant transformation of fibroids — this is a high-yield
                  exam fact</li>
                <li>LMS arises de novo from myometrium; distinct molecular signature</li>
                <li>Prevalence: ~1 in 350–500 women undergoing surgery for presumed fibroids</li>
                <li>Red flags for LMS: rapid growth, post-menopausal new fibroid, irregular margins on MRI,
                  heterogeneous
                  signal</li>
                <li>No reliable pre-operative method to exclude LMS — hence morcellation controversy</li>
              </ul>
            </div>
          </div>
        </div>
      </details>

      <details class="collapse-panel reveal">
        <summary>⚠️ High-Yield Exam Pearl — Red Degeneration <span class="collapse-hint">click to expand</span>
        </summary>
        <div class="collapse-content">
          <div class="pearl-callout">
            <div class="pearl-title">⚠️ High-Yield Exam Pearl</div>
            <p style="font-size:0.85rem;color:var(--text-1);line-height:1.7;">
              <strong>Red/Carneous degeneration</strong> is unique to pregnancy. The fibroid undergoes acute
              haemorrhagic
              infarction as its blood supply cannot keep pace with growth stimulated by pregnancy hormones. Clinical
              features: sudden-onset localised uterine tenderness, low-grade fever, leucocytosis, raised CRP — mimics
              appendicitis. Management is conservative: analgesia (paracetamol, opioids), hydration, NSAIDs (avoid after
              28
              weeks). It is self-limiting and does NOT require surgery.
            </p>
          </div>
        </div>
      </details>
    </div>
  </section>

  <!-- ============================================================
     SECTION 7 — DIFFERENTIAL DIAGNOSIS
     ============================================================ -->
  <section id="differential" aria-label="Differential diagnosis">
    <div class="container">
      <p class="section-label reveal">07 — Differential Diagnosis</p>
      <h2 class="section-title reveal">Differentials to <em>Exclude</em></h2>
      <p class="lead reveal">An enlarged, irregular uterus with AUB has a broad differential. Clinical examination,
        imaging, and sometimes hysteroscopy or endometrial biopsy are required to differentiate.</p>

      <details class="collapse-panel reveal">
        <summary>Differential Diagnosis Comparison Table <span class="collapse-hint">click to expand</span></summary>
        <div class="collapse-content">
          <table class="diff-table">
            <thead>
              <tr>
                <th>Condition</th>
                <th>Key Clinical Features</th>
                <th>Imaging Characteristic</th>
                <th>Distinguishing Feature</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Adenomyosis</td>
                <td>Dysmenorrhoea, menorrhagia; diffusely enlarged "globular" uterus; tender on bimanual</td>
                <td>USS: heterogeneous myometrium, "venetian blind" shadowing. MRI: junctional zone &gt;12 mm</td>
                <td class="key-diff">Tenderness + diffuse enlargement (vs discrete fibroids). Often coexist.</td>
              </tr>
              <tr>
                <td>Endometrial Polyp</td>
                <td>AUB/IMB, often post-menopausal or OCP users; uterus often normal size</td>
                <td>USS: hyperechoic endometrial lesion. Saline infusion sonography (SIS): pedunculated intracavitary
                  mass
                </td>
                <td class="key-diff">Normal uterine size; polyp is entirely endometrial (vs fibroid = myometrial origin)
                </td>
              </tr>
              <tr>
                <td>Leiomyosarcoma (LMS)</td>
                <td>Rapid uterine growth (esp. post-menopausal); pelvic pain; abnormal uterine bleeding</td>
                <td>MRI: irregular margins, heterogeneous signal on T2, central necrosis, diffusion restriction</td>
                <td class="key-diff">Rapid growth post-menopause; MRI features of malignancy. Pre-op diagnosis
                  impossible in
                  most cases.</td>
              </tr>
              <tr>
                <td>Ovarian Mass</td>
                <td>May be asymptomatic or cause pressure; adnexal mass on exam</td>
                <td>USS: separate from uterus; complex features suggest malignancy (septae, solid areas, ascites)</td>
                <td class="key-diff">Pedunculated fibroid FIGO Type 7 can mimic ovarian mass — follow mass to uterus on
                  USS/MRI</td>
              </tr>
              <tr>
                <td>Pregnancy</td>
                <td>Missed period, positive βhCG; uterine enlargement</td>
                <td>USS: intrauterine gestational sac; CRL; fetal heart</td>
                <td class="key-diff">Always exclude pregnancy — βhCG is mandatory in women of reproductive age</td>
              </tr>
              <tr>
                <td>Endometrial Carcinoma</td>
                <td>Post-menopausal bleeding (PMB) or pre-menopausal with risk factors (obesity, DM, PCOS, Lynch)</td>
                <td>USS: thickened endometrium (&gt;4 mm post-menopausal); MRI for staging</td>
                <td class="key-diff">PMB requires endometrial biopsy regardless of fibroid presence. Fibroids do NOT
                  cause
                  PMB.</td>
              </tr>
              <tr>
                <td>Broad Ligament Fibroid</td>
                <td>Lateral pelvic mass; may displace ureter, bladder, bowel</td>
                <td>USS/MRI: mass arising lateral to uterus within broad ligament; separate ovaries</td>
                <td class="key-diff">Can mimic ovarian mass or retroperitoneal tumour; MRI is key to confirm uterine
                  origin
                </td>
              </tr>
              <tr>
                <td>Endometriosis</td>
                <td>Dysmenorrhoea, dyspareunia, dyschezia; fixed, retroverted uterus</td>
                <td>USS: endometriomas ("ground-glass" cysts); MRI: DIE nodules</td>
                <td class="key-diff">Fixed, tender uterus with adnexal masses. Often coexists with fibroids (20–30%).
                </td>
              </tr>
            </tbody>
          </table>
        </div>
      </details>
    </div>
  </section>

  <!-- ============================================================
     SECTION 8 — DIAGNOSIS WORKFLOW
     ============================================================ -->
  <section id="diagnosis" aria-label="Diagnosis workflow">
    <div class="orb orb-2" style="top:20%;left:-10%;opacity:0.1;"></div>
    <div class="container">
      <p class="section-label reveal">08 — Diagnosis</p>
      <h2 class="section-title reveal">Diagnostic <em>Workflow</em></h2>
      <p class="lead reveal">A structured approach moving from history and examination through imaging to endoscopy and
        tissue sampling where indicated. The diagnosis is often made on USS; MRI is reserved for specific indications.
      </p>

      <details class="collapse-panel reveal">
        <summary>Diagnostic Steps 1–8 — History → USS → MRI → Biopsy <span class="collapse-hint">click to expand</span>
        </summary>
        <div class="collapse-content">
          <div class="dx-flow" id="dxFlow">
            <div class="dx-step" data-step="0">
              <div class="dx-step-line"></div>
              <div class="dx-number">1</div>
              <div class="dx-content">
                <h4>History</h4>
                <p>Characterise bleeding pattern (duration, frequency, amount), pain, pressure symptoms, reproductive
                  history, contraception, medications, family history of fibroids or hereditary leiomyomatosis.</p>
                <div class="dx-detail">
                  <strong style="color:var(--purple);">PALM-COEIN AUB classification:</strong> Document whether AUB is
                  heavy
                  menstrual bleeding (HMB), intermenstrual (IMB), post-coital (PCB), or post-menopausal (PMB). PALM =
                  Polyp,
                  Adenomyosis, Leiomyoma, Malignancy/hyperplasia. COEIN = Coagulopathy, Ovulatory dysfunction,
                  Endometrial,
                  Iatrogenic, Not yet classified.
                </div>
              </div>
            </div>

            <div class="dx-step" data-step="1">
              <div class="dx-step-line"></div>
              <div class="dx-number">2</div>
              <div class="dx-content">
                <h4>Physical Examination</h4>
                <p>Abdominal palpation for suprapubic mass; bimanual examination; speculum examination.</p>
                <div class="dx-detail">
                  Classic findings: enlarged, <strong>irregularly</strong> shaped, <strong>firm</strong>,
                  <strong>non-tender</strong>, <strong>mobile</strong> uterus. Speculum: check cervix, look for
                  prolapsed
                  fibroid. Assess for anaemia signs.
                </div>
              </div>
            </div>

            <div class="dx-step" data-step="2">
              <div class="dx-step-line"></div>
              <div class="dx-number">3</div>
              <div class="dx-content">
                <h4>Blood Tests</h4>
                <p>Baseline investigations to assess impact and exclude differentials.</p>
                <div class="dx-indications">
                  <span class="badge badge-purple">FBC (anaemia)</span>
                  <span class="badge badge-teal">Ferritin</span>
                  <span class="badge badge-purple">βhCG (exclude pregnancy)</span>
                  <span class="badge badge-teal">TFTs (thyroid AUB)</span>
                  <span class="badge badge-amber">Coagulation screen (if HMB from adolescence → exclude vWD)</span>
                  <span class="badge badge-pink">LFTs + renal function (pre-operative)</span>
                </div>
              </div>
            </div>

            <div class="dx-step" data-step="3">
              <div class="dx-step-line"></div>
              <div class="dx-number">4</div>
              <div class="dx-content">
                <h4>Pelvic Ultrasound — First-Line Imaging</h4>
                <p>Transvaginal ultrasound (TVUSS) is the investigation of choice. Superior resolution for fibroid
                  characterisation, especially submucosal involvement.</p>
                <div class="dx-detail">
                  <strong style="color:var(--purple);">USS findings:</strong> Hypoechoic or heterogeneous whorled mass
                  within myometrium; may have acoustic shadowing. Document: number, size, location (FIGO type where
                  possible), relationship to endometrium and serosa, vascularity on Doppler. Transabdominal (TAUS)
                  useful
                  for large fibroids extending above pubic symphysis.
                </div>
              </div>
            </div>

            <div class="dx-step" data-step="4">
              <div class="dx-step-line"></div>
              <div class="dx-number">5</div>
              <div class="dx-content">
                <h4>Saline Infusion Sonography (SIS) / Sonohysterography</h4>
                <p>Instillation of saline into cavity via transcervical catheter during USS. First-line for evaluation
                  of
                  endometrial cavity and submucosal fibroid characterisation.</p>
                <div class="dx-detail">
                  Superior to TVUSS alone for submucosal fibroids. Allows FIGO subtype classification (Types 0–2) for
                  hysteroscopic planning. Also evaluates for endometrial polyps simultaneously.
                </div>
              </div>
            </div>

            <div class="dx-step" data-step="5">
              <div class="dx-step-line"></div>
              <div class="dx-number">6</div>
              <div class="dx-content">
                <h4>MRI Pelvis — Specific Indications</h4>
                <p>Not routine, but gold standard when complex anatomy, malignancy suspicion, or pre-procedural planning
                  requires it.</p>
                <div class="dx-indications">
                  <span class="badge badge-purple">Pre-UAE mapping</span>
                  <span class="badge badge-purple">Pre-HIFU/RFA planning</span>
                  <span class="badge badge-pink">Atypical USS features (LMS exclusion)</span>
                  <span class="badge badge-teal">Multiple fibroids (operative planning)</span>
                  <span class="badge badge-amber">Indeterminate pelvic mass</span>
                  <span class="badge badge-teal">Evaluate junctional zone (adenomyosis)</span>
                </div>
                <div class="dx-detail" style="margin-top:10px;">
                  <strong style="color:var(--purple);">MRI fibroid signal:</strong> Low signal intensity on T2 (dense
                  smooth
                  muscle + collagen). Fibroids with high T2 signal or restricted diffusion raise concern for
                  leiomyosarcoma.
                  Gadolinium contrast: fibroids enhance variably; degenerated fibroids may not enhance.
                </div>
              </div>
            </div>

            <div class="dx-step" data-step="6">
              <div class="dx-step-line"></div>
              <div class="dx-number">7</div>
              <div class="dx-content">
                <h4>Hysteroscopy</h4>
                <p>Direct endoscopic visualisation of the endometrial cavity. Diagnostic and therapeutic. Gold standard
                  for
                  submucosal fibroid assessment.</p>
                <div class="dx-detail">
                  Indicated when: endometrial cavity pathology suspected; SIS inconclusive; pre-operative assessment of
                  FIGO
                  Types 0–2 for resectability; failed medical management with suspected cavity pathology. Can be
                  combined
                  with endometrial biopsy.
                </div>
              </div>
            </div>

            <div class="dx-step" data-step="7">
              <div class="dx-number">8</div>
              <div class="dx-content">
                <h4>Endometrial Biopsy</h4>
                <p>To exclude endometrial hyperplasia or carcinoma. Not routinely required for fibroid diagnosis itself.
                </p>
                <div class="dx-detail">
                  <strong style="color:var(--amber);">Indications for endometrial biopsy in fibroid patients:</strong>
                  Age
                  ≥45 with AUB, or any age with risk factors for endometrial cancer (obesity, DM, PCOS, tamoxifen, Lynch
                  syndrome, treatment-resistant AUB). Post-menopausal bleeding mandates biopsy regardless.
                </div>
              </div>
            </div>
          </div>

          <!-- Indian Diagnosis Context -->
          <div
            style="margin-top:20px;padding:16px 20px;background:rgba(255,183,77,0.06);border:1px solid rgba(255,183,77,0.2);border-radius:var(--radius-sm);">
            <p style="font-size:0.82rem;color:var(--amber);margin-bottom:6px;"><strong>🇮🇳 Indian Diagnostic
                Context:</strong></p>
            <ul style="list-style:none;font-size:0.8rem;color:var(--text-2);">
              <li style="padding:3px 0;">• Transabdominal USS often first-line due to patient acceptability and wider
                equipment availability</li>
              <li style="padding:3px 0;">• SIS availability limited to tertiary/teaching hospitals</li>
              <li style="padding:3px 0;">• MRI access: readily available in metro cities; may require referral from
                district level</li>
              <li style="padding:3px 0;">• Office hysteroscopy growing but not universally available — outpatient
                setting preferred where possible</li>
            </ul>
          </div>
        </div>
      </details>
    </div>
  </section>

  <!-- ============================================================
     SECTION 9 — MANAGEMENT
     ============================================================ -->
  <section id="management" aria-label="Management algorithm">
    <div class="container">
      <p class="section-label reveal">09 — Management</p>
      <h2 class="section-title reveal">Management <em>Algorithm</em></h2>
      <p class="lead reveal">Management is individualised based on symptom severity, fibroid characteristics (size,
        location, number), reproductive wishes, age, patient preference, and available resources. A stepwise approach is
        recommended.</p>

      <details class="collapse-panel reveal">
        <summary>Management Decision Tree <span class="collapse-hint">click to expand</span></summary>
        <div class="collapse-content">
          <div class="mgmt-decision">
            <div
              style="font-family:var(--font-mono);font-size:0.78rem;color:var(--text-2);line-height:2.2;overflow-x:auto;">
              <span style="color:var(--text-1);font-size:0.9rem;font-weight:600;">FIBROID DIAGNOSED ON HISTORY /
                EXAMINATION
                / USS</span>
              <br>
              ├─ <span style="color:var(--green);">ASYMPTOMATIC</span>
              │ └─→ <span style="color:var(--teal);">Expectant management</span> — annual USS, reassure, explain symptom
              red
              flags
              <br>
              ├─ <span style="color:var(--amber);">SYMPTOMATIC — FERTILITY DESIRED</span>
              │ ├─→ <span style="color:var(--teal);">Medical 1st line:</span> TXA / NSAIDs / hormonal (if cavity not
              distorted: LNG-IUS)
              │ ├─→ <span style="color:var(--teal);">GnRH agonist:</span> pre-op downsizing (max 3–6 months + add-back
              HRT)
              │ ├─→ <span style="color:var(--purple);">Myomectomy</span> (hysteroscopic / laparoscopic / open —
              location-dependent)
              │ └─→ <span style="color:var(--pink);">UAE:</span> relative contraindication if planning pregnancy (not
              absolute per NICE)
              <br>
              ├─ <span style="color:var(--amber);">SYMPTOMATIC — FAMILY COMPLETE / NO FERTILITY DESIRE</span>
              │ ├─→ <span style="color:var(--teal);">Medical:</span> LNG-IUS, OCP, GnRH agonist/antagonist, TXA, NSAIDs
              │ ├─→ <span style="color:var(--purple);">UAE</span> — preferred non-surgical option (NICE NG88)
              │ ├─→ <span style="color:var(--purple);">Radiofrequency ablation / MRgFUS</span>
              │ ├─→ <span style="color:var(--purple);">Myomectomy</span> (if wants to retain uterus)
              │ └─→ <span style="color:var(--pink);">Hysterectomy</span> — definitive; laparoscopic / vaginal /
              abdominal
              <br>
              └─ <span style="color:var(--red);">EMERGENCY — ACUTE SEVERE HAEMORRHAGE</span>
              └─→ <span style="color:var(--red);">Resuscitate → IV TXA → Balloon tamponade → UAE/Hysterectomy</span>
            </div>
          </div>
        </div>
      </details>

      <details class="collapse-panel reveal">
        <summary>Treatment Pathways — Expectant / Medical / Interventional / Surgical <span class="collapse-hint">click
            to expand</span></summary>
        <div class="collapse-content">
          <div class="mgmt-pathways">
            <div class="pathway-card expectant">
              <h4>Expectant</h4>
              <ul>
                <li>Asymptomatic or mildly symptomatic</li>
                <li>Annual pelvic USS surveillance</li>
                <li>Patient education: symptom monitoring</li>
                <li>Iron supplementation if borderline anaemia</li>
                <li>Reassurance re: malignant transformation myth</li>
                <li>Natural regression expected post-menopause</li>
              </ul>
            </div>
            <div class="pathway-card medical">
              <h4>Medical</h4>
              <ul>
                <li>Tranexamic acid — first-line HMB</li>
                <li>NSAIDs — dysmenorrhoea + modest AUB</li>
                <li>OCP / Progestogen — AUB control</li>
                <li>LNG-IUS — if cavity not distorted</li>
                <li>GnRH agonists — pre-op, 3–6 months</li>
                <li>GnRH antagonists (relugolix) — oral, newer</li>
                <li>Iron ± EPO — pre-op anaemia correction</li>
              </ul>
            </div>
            <div class="pathway-card interv">
              <h4>Interventional</h4>
              <ul>
                <li>UAE — uterine artery embolisation</li>
                <li>MRgFUS — MRI-guided focused ultrasound</li>
                <li>Radiofrequency ablation (Acessa/Sonata)</li>
                <li>Hysteroscopic myomectomy (Types 0–2)</li>
                <li>Endometrial ablation (+ fibroid — selected)</li>
              </ul>
            </div>
            <div class="pathway-card surgical">
              <h4>Surgical</h4>
              <ul>
                <li>Hysteroscopic myomectomy</li>
                <li>Laparoscopic myomectomy</li>
                <li>Abdominal (open) myomectomy</li>
                <li>Laparoscopic hysterectomy</li>
                <li>Abdominal/vaginal hysterectomy</li>
                <li>Note: FDA 2014 power morcellator warning</li>
              </ul>
            </div>
          </div>
        </div>
      </details>

      <!-- India Practice Note -->
      <details class="collapse-panel reveal" style="border-color:rgba(255,183,77,0.3);">
        <summary style="color:var(--amber);">🇮🇳 India Practice Note — Management Realities <span
            class="collapse-hint">click to expand</span></summary>
        <div class="collapse-content">
          <div style="font-size:0.85rem;color:var(--text-2);line-height:1.8;">
            <p style="margin-bottom:12px;"><strong style="color:var(--text-1);">FOGSI stepwise approach:</strong>
              Medical → Interventional → Surgical. Conservative management emphasised where possible, considering
              patient preferences and resource constraints.</p>
            <div style="display:grid;grid-template-columns:1fr 1fr;gap:16px;margin-bottom:16px;">
              <div>
                <p style="font-size:0.78rem;color:var(--green);font-family:var(--font-mono);margin-bottom:6px;">WIDELY
                  AVAILABLE</p>
                <ul style="list-style:none;font-size:0.82rem;">
                  <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Tranexamic acid <span
                      class="india-badge available">₹5–10/tab</span></li>
                  <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Mefenamic acid (NSAID of choice)
                    <span class="india-badge available">₹3–5/tab</span>
                  </li>
                  <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">GnRH agonist — Leuprolide Depot
                    <span class="india-badge available">₹1500–2500/dose</span>
                  </li>
                  <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Mifepristone 25–50mg daily <span
                      class="india-badge available">Off-label, ₹15–25/tab</span></li>
                  <li style="padding:4px 0;">Open myomectomy — <strong style="color:var(--text-1);">most common surgical
                      approach</strong></li>
                </ul>
              </div>
              <div>
                <p style="font-size:0.78rem;color:var(--amber);font-family:var(--font-mono);margin-bottom:6px;">LIMITED
                  / TERTIARY ONLY</p>
                <ul style="list-style:none;font-size:0.82rem;">
                  <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">LNG-IUS (Mirena) <span
                      class="india-badge limited">₹8000–12000</span></li>
                  <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">UAE — select centres (AIIMS, CMC
                    Vellore, Amrita) <span class="india-badge limited">Tertiary</span></li>
                  <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Laparoscopic myomectomy — growing
                    via FOGSI/MIS workshops <span class="india-badge limited">Training ↑</span></li>
                  <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">Relugolix <span
                      class="india-badge unavailable">Not available</span></li>
                  <li style="padding:4px 0;">MRgFUS / Radiofrequency ablation <span
                      class="india-badge unavailable">Research only</span></li>
                </ul>
              </div>
            </div>
            <p style="font-size:0.82rem;"><strong style="color:var(--amber);">Mifepristone:</strong> Extensively studied
              in Indian RCTs. 25mg daily × 3 months → fibroid volume reduction 40–50%, amenorrhoea 60–80%. Side effects:
              reversible endometrial hyperplasia, anti-glucocorticoid. <em style="color:var(--text-3);">Off-label but
                commonly prescribed in Indian clinical practice.</em></p>
            <p style="font-size:0.82rem;margin-top:8px;"><strong style="color:var(--amber);">Hysterectomy:</strong> Most
              commonly performed major gynaecological surgery in India. TAH predominates; TLH growing in metro centres.
              FOGSI recommends ovarian conservation in premenopausal women.</p>
          </div>
        </div>
      </details>
    </div>
  </section>

  <!-- ============================================================
     SECTION 10 — DRUGS
     ============================================================ -->
  <section id="drugs" aria-label="Medical management — drugs">
    <div class="container">
      <p class="section-label reveal">10 — Medical Therapy</p>
      <h2 class="section-title reveal">Pharmacological <em>Options</em></h2>
      <p class="lead reveal">Hover or tap each card to reveal clinical details, mechanism of action, and key warnings.
        Medical therapy aims to control symptoms; it does not permanently shrink or eliminate fibroids (except GnRH
        agonists — temporarily).</p>
      <div class="reveal" style="margin-bottom:16px;text-align:right;">
        <button id="showAllDrugs" onclick="toggleAllDrugCards()"
          style="background:var(--bg-card-2);border:1px solid var(--border);border-radius:100px;padding:8px 18px;font-family:var(--font-mono);font-size:0.75rem;color:var(--text-2);cursor:pointer;letter-spacing:0.05em;transition:all 0.3s;">Show
          All Details</button>
      </div>

      <div class="drugs-grid reveal">

        <!-- TRANEXAMIC ACID -->
        <div class="drug-card" tabindex="0" role="button" aria-label="Tranexamic Acid - click to flip">
          <div class="drug-card-inner">
            <div class="drug-front">
              <div>
                <div class="drug-class">Antifibrinolytic</div>
                <div class="drug-name">Tranexamic Acid</div>
                <div class="drug-example">Cyklokapron, Lysteda</div>
              </div>
              <div>
                <span class="badge badge-green">First-Line HMB</span>
                <div class="drug-flip-hint">hover / tap for details →</div>
              </div>
            </div>
            <div class="drug-back">
              <h5>Mechanism &amp; Use</h5>
              <ul>
                <li>Inhibits plasminogen → antifibrinolytic → stabilises clot at endometrial surface</li>
                <li>Taken during menstruation only (up to 5 days)</li>
                <li>Reduces blood loss ~30–60%</li>
                <li>Non-hormonal — suitable for women wanting to conceive</li>
                <li>Dose: 1g TDS–QDS orally during heavy days</li>
                <li>IV form used in emergency haemorrhage</li>
              </ul>
              <div class="drug-warning">⚠️ Caution: history of thromboembolism. Does NOT shrink fibroids.</div>
            </div>
          </div>
        </div>

        <!-- NSAIDs -->
        <div class="drug-card" tabindex="0" role="button">
          <div class="drug-card-inner">
            <div class="drug-front">
              <div>
                <div class="drug-class">NSAID / COX Inhibitor</div>
                <div class="drug-name">Mefenamic Acid / Naproxen</div>
                <div class="drug-example">Ponstan, Naprosyn</div>
              </div>
              <div>
                <span class="badge badge-teal">Dysmenorrhoea</span>
                <div class="drug-flip-hint">hover / tap for details →</div>
              </div>
            </div>
            <div class="drug-back">
              <h5>Mechanism &amp; Use</h5>
              <ul>
                <li>Inhibits prostaglandin synthesis (COX-1/2) → reduces uterine contractions</li>
                <li>Reduces blood loss ~20–30% (modest effect on AUB)</li>
                <li>Primarily for dysmenorrhoea associated with fibroids</li>
                <li>Start at onset of menstruation</li>
                <li>Combined with TXA for additive effect</li>
              </ul>
              <div class="drug-warning">⚠️ Avoid in renal impairment, PUD, asthma. Avoid after 28 wks pregnancy.</div>
            </div>
          </div>
        </div>

        <!-- OCP -->
        <div class="drug-card" tabindex="0" role="button">
          <div class="drug-card-inner">
            <div class="drug-front">
              <div>
                <div class="drug-class">Combined Hormonal Contraceptive</div>
                <div class="drug-name">Combined Oral Contraceptive</div>
                <div class="drug-example">Levonorgestrel/EE, Norethisterone/EE</div>
              </div>
              <div>
                <span class="badge badge-purple">AUB Control</span>
                <div class="drug-flip-hint">hover / tap for details →</div>
              </div>
            </div>
            <div class="drug-back">
              <h5>Mechanism &amp; Use</h5>
              <ul>
                <li>Suppresses endometrial proliferation → lighter, more predictable bleeds</li>
                <li>Does NOT reliably reduce fibroid size (may cause slight reduction or growth — variable)</li>
                <li>Reduces dysmenorrhoea and AUB</li>
                <li>Useful in perimenopausal women with fibroids + AUB</li>
                <li>Evidence on fibroid growth with OCP is mixed</li>
              </ul>
              <div class="drug-warning">⚠️ Standard OCP contraindications apply (VTE risk, migraine with aura, etc).
              </div>
            </div>
          </div>
        </div>

        <!-- LNG-IUS -->
        <div class="drug-card" tabindex="0" role="button">
          <div class="drug-card-inner">
            <div class="drug-front">
              <div>
                <div class="drug-class">Progestogen-releasing IUD</div>
                <div class="drug-name">LNG-IUS</div>
                <div class="drug-example">Mirena (52mg levonorgestrel)</div>
              </div>
              <div>
                <span class="badge badge-purple">Long-term AUB</span>
                <div class="drug-flip-hint">hover / tap for details →</div>
              </div>
            </div>
            <div class="drug-back">
              <h5>Mechanism &amp; Use</h5>
              <ul>
                <li>Local progestogen → endometrial atrophy → amenorrhoea in ~40% at 12 months</li>
                <li>Reduces HMB by ~90% over 12 months</li>
                <li>Effective for up to 5–8 years; reversible</li>
                <li>NICE first-line for HMB in women not desiring pregnancy in short-term</li>
                <li>Also treats adenomyosis (common co-condition)</li>
              </ul>
              <div class="drug-warning">⚠️ CONTRAINDICATED if endometrial cavity significantly distorted by submucosal
                fibroid — insertion impossible / expulsion risk. USS essential before insertion.</div>
            </div>
          </div>
        </div>

        <!-- GnRH AGONIST -->
        <div class="drug-card" tabindex="0" role="button">
          <div class="drug-card-inner">
            <div class="drug-front">
              <div>
                <div class="drug-class">GnRH Agonist</div>
                <div class="drug-name">Leuprolide / Goserelin</div>
                <div class="drug-example">Lupron, Zoladex, Decapeptyl</div>
              </div>
              <div>
                <span class="badge badge-pink">Pre-op Downsizing</span>
                <div class="drug-flip-hint">hover / tap for details →</div>
              </div>
            </div>
            <div class="drug-back">
              <h5>Mechanism &amp; Use</h5>
              <ul>
                <li>Continuous GnRH stimulation → pituitary desensitisation → ↓ LH/FSH → hypoestrogenic state</li>
                <li>Initial "flare" in first 2 weeks (↑ gonadotrophins) — use short-term progestogen cover</li>
                <li>Reduces fibroid volume ~35–60% over 3 months</li>
                <li>Pre-operative use: improve anaemia, reduce surgical blood loss, facilitate laparoscopic/vaginal
                  approach</li>
                <li><strong>Max duration: 3–6 months</strong> — bone density loss beyond this</li>
                <li>Add-back HRT (low-dose E2 + progestogen) if &gt;3 months to protect bone</li>
                <li>Fibroids regrow on stopping (rebound within 3–6 months)</li>
              </ul>
              <div class="drug-warning">⚠️ Hypoestrogenic side effects: hot flushes, bone loss (reversible), vaginal
                dryness, mood changes. NOT for long-term use. NOT curative.</div>
            </div>
          </div>
        </div>

        <!-- GnRH ANTAGONIST -->
        <div class="drug-card" tabindex="0" role="button">
          <div class="drug-card-inner">
            <div class="drug-front">
              <div>
                <div class="drug-class">GnRH Antagonist</div>
                <div class="drug-name">Relugolix / Elagolix</div>
                <div class="drug-example">Myfembree (relugolix+E2+NETA) · Oriahnn</div>
              </div>
              <div>
                <span class="badge badge-purple">Newer · Oral</span>
                <div class="drug-flip-hint">hover / tap for details →</div>
              </div>
            </div>
            <div class="drug-back">
              <h5>Mechanism &amp; Use</h5>
              <ul>
                <li>Competitive GnRH receptor blockade → immediate, dose-dependent suppression of LH/FSH — no flare
                  effect</li>
                <li>Oral (once daily) — major advantage over injectable GnRH agonists</li>
                <li>Combined with low-dose oestrogen + progestogen ("add-back") to offset hypoestrogenic effects</li>
                <li>Myfembree (relugolix 40mg + E2 1mg + NETA 0.5mg): FDA approved May 2021 for HMB in premenopausal
                  women with fibroids</li>
                <li>Reduces HMB significantly (LIBERTY trials); also approved for endometriosis</li>
                <li>UK/EU availability more limited — check local formulary</li>
              </ul>
              <div class="drug-warning">⚠️ Contraindicated in pregnancy; not for women planning conception. Bone density
                monitoring for extended use. Liver function monitoring for elagolix.</div>
            </div>
          </div>
        </div>

        <!-- SPRMs (Ulipristal) -->
        <div class="drug-card" tabindex="0" role="button">
          <div class="drug-card-inner">
            <div class="drug-front">
              <div>
                <div class="drug-class">Selective Progesterone Receptor Modulator</div>
                <div class="drug-name">Ulipristal Acetate</div>
                <div class="drug-example">Esmya (EU/UK — SUSPENDED)</div>
              </div>
              <div>
                <span class="badge badge-red">⚠️ SUSPENDED 2020</span>
                <div class="drug-flip-hint">hover / tap for details →</div>
              </div>
            </div>
            <div class="drug-back">
              <h5>Historical Context &amp; Safety</h5>
              <ul>
                <li>Was approved in EU for pre-operative and intermittent treatment of moderate–severe fibroid symptoms
                </li>
                <li>Mechanism: partial agonist/antagonist at progesterone receptor → fibroid shrinkage, amenorrhoea
                  without full hypoestrogenic state</li>
                <li>EMA 2018: restricted use due to rare but serious hepatotoxicity</li>
                <li>EMA/MHRA 2020: marketing suspension due to continued hepatotoxicity reports including liver failure
                  requiring transplant</li>
                <li>Currently NOT recommended anywhere for fibroids</li>
                <li>Still referenced in older guidelines and exams — must know its status</li>
                <li><strong>Indian context:</strong> CDSCO regulatory status may differ from EMA — verify local
                  availability before exam answers; however, hepatotoxicity concerns apply universally</li>
              </ul>
              <div class="drug-warning">🚫 SUSPENDED — NOT FOR CLINICAL USE. Serious hepatotoxicity including liver
                failure. Mention in exams as historically important SPRM with known safety issue.</div>
            </div>
          </div>
        </div>

        <!-- IRON SUPPLEMENTATION -->
        <div class="drug-card" tabindex="0" role="button">
          <div class="drug-card-inner">
            <div class="drug-front">
              <div>
                <div class="drug-class">Haematinics</div>
                <div class="drug-name">Iron Supplementation</div>
                <div class="drug-example">Ferrous sulphate, IV Ferric carboxymaltose</div>
              </div>
              <div>
                <span class="badge badge-green">Anaemia Correction</span>
                <div class="drug-flip-hint">hover / tap for details →</div>
              </div>
            </div>
            <div class="drug-back">
              <h5>Mechanism &amp; Use</h5>
              <ul>
                <li>Replaces iron stores depleted by chronic AUB</li>
                <li>Oral: ferrous sulphate 200mg BD–TDS; check Hb at 4 weeks</li>
                <li>IV: ferric carboxymaltose (Ferinject) — preferred if oral intolerance, severe deficiency, or
                  pre-operative rapid correction required</li>
                <li>Target: Hb ≥10 g/dL before elective surgery</li>
                <li>Combined with GnRH agonist for maximum pre-operative Hb improvement</li>
                <li>Patient blood management (PBM): reduces need for allogenic blood transfusion</li>
              </ul>
              <div class="drug-warning">⚠️ Oral iron: constipation, GI upset — take with food. IV iron: anaphylaxis risk
                — resuscitation facilities required.</div>
            </div>
          </div>
        </div>

        <!-- PROGESTOGENS -->
        <div class="drug-card" tabindex="0" role="button">
          <div class="drug-card-inner">
            <div class="drug-front">
              <div>
                <div class="drug-class">Progestogen</div>
                <div class="drug-name">Norethisterone / Medroxyprogesterone</div>
                <div class="drug-example">Primolut N, Provera, Depo-Provera</div>
              </div>
              <div>
                <span class="badge badge-teal">AUB Control</span>
                <div class="drug-flip-hint">hover / tap for details →</div>
              </div>
            </div>
            <div class="drug-back">
              <h5>Mechanism &amp; Use</h5>
              <ul>
                <li>Endometrial suppression via progestogen receptor</li>
                <li>Norethisterone 5mg TDS (days 5–26) — reduces AUB; useful short-term or cyclically</li>
                <li>Depo-Provera (DMPA) injection: amenorrhoea in many; useful when other options declined</li>
                <li>High-dose norethisterone: emergency treatment for acute HMB (5mg TDS until bleeding controlled)</li>
                <li>Does NOT reliably shrink fibroids; may theoretically stimulate growth via PR</li>
              </ul>
              <div class="drug-warning">⚠️ High-dose norethisterone: VTE risk; headache; weight gain. DMPA: delayed
                return of fertility (up to 12+ months).</div>
            </div>
          </div>
        </div>

        <!-- MIFEPRISTONE (INDIA-RELEVANT) -->
        <div class="drug-card" tabindex="0" role="button" aria-label="Mifepristone - click to flip">
          <div class="drug-card-inner">
            <div class="drug-front">
              <div>
                <div class="drug-class">SPRM (Antiprogestogen)</div>
                <div class="drug-name">Mifepristone</div>
                <div class="drug-example">RU-486 · 25–50mg daily</div>
              </div>
              <div>
                <span class="badge badge-amber">India — Off-label</span>
                <span class="india-badge available" style="margin-top:6px;display:inline-flex;">₹15–25/tab</span>
                <div class="drug-flip-hint">hover / tap for details →</div>
              </div>
            </div>
            <div class="drug-back">
              <h5>Mechanism &amp; Use</h5>
              <ul>
                <li>Selective progesterone receptor modulator → blocks progesterone action on fibroid</li>
                <li>Dose: 25mg daily × 3 months (Indian RCT regimen)</li>
                <li>Fibroid volume reduction: 40–50% by 3 months</li>
                <li>Amenorrhoea rate: 60–80% during treatment</li>
                <li>Extensively studied in Indian randomised controlled trials (JOGI, IJOG)</li>
                <li>Used as pre-operative downsizing agent (alternative to GnRH agonists)</li>
                <li>No bone loss (advantage over GnRH agonists)</li>
              </ul>
              <div class="drug-warning">⚠️ Reversible endometrial hyperplasia (PAEC — progesterone receptor modulator
                associated endometrial changes). Anti-glucocorticoid effects at higher doses. Not recommended in
                pregnancy. Off-label use in India — CDSCO has not specifically approved for fibroids.</div>
            </div>
          </div>
        </div>

      </div>
    </div>
  </section>

  <!-- ============================================================
     SECTION 11 — PROCEDURES
     ============================================================ -->
  <section id="procedures" aria-label="Surgical and interventional procedures">
    <div class="orb orb-3" style="top:5%;left:-5%;opacity:0.08;"></div>
    <div class="container">
      <p class="section-label reveal">11 — Procedures</p>
      <h2 class="section-title reveal">Surgical &amp; <em>Interventional</em> Options</h2>
      <p class="lead reveal">Procedural management spans minimally-invasive interventional radiology through endoscopy
        to major abdominal surgery. Choice depends on fibroid characteristics, fertility goals, patient fitness, and
        available expertise.</p>

      <details class="collapse-panel reveal">
        <summary>Procedure Details — Endoscopic, Laparoscopic, Open, IR, Energy-based <span class="collapse-hint">click
            to expand</span></summary>
        <div class="collapse-content">
          <div class="proc-timeline">

            <div class="proc-item">
              <div class="proc-dot">🔭</div>
              <div class="proc-type">Endoscopic</div>
              <div class="proc-name">Hysteroscopic Myomectomy</div>
              <div class="proc-desc">FIGO Types 0–2. Resection of submucosal fibroid using resectoscope loop electrode
                or
                morcellator. Day case. Preserves fertility. Gold standard for submucosal fibroids. ESGE difficulty score
                guides planning.</div>
              <div style="margin-top:10px;"><span class="badge badge-green">Fertility Sparing</span></div>
            </div>
            <div class="proc-item">
              <div class="proc-dot">🔬</div>
              <div class="proc-type">Laparoscopic</div>
              <div class="proc-name">Laparoscopic Myomectomy</div>
              <div class="proc-desc">Subserosal (FIGO 5–7) and selected intramural fibroids. Shorter recovery than open.
                Requires advanced laparoscopic skills. Containment bag morcellation used (FDA guidance post-2014).
                Subsequent pregnancy: CS often recommended to reduce uterine rupture risk.</div>
              <div style="margin-top:10px;"><span class="badge badge-green">Fertility Sparing</span></div>
            </div>
            <div class="proc-item">
              <div class="proc-dot">✂️</div>
              <div class="proc-type">Open Surgery</div>
              <div class="proc-name">Abdominal Myomectomy</div>
              <div class="proc-desc">Large (&gt;10cm), multiple, or inaccessible fibroids. Direct uterine incision,
                fibroid
                enucleation, multi-layer closure. Gold standard for fertility preservation when large/multiple. Uterine
                compression sutures + vasopressin infusion reduce intra-op blood loss.</div>
              <div style="margin-top:10px;"><span class="badge badge-green">Fertility Sparing</span></div>
            </div>
            <div class="proc-item">
              <div class="proc-dot">🩺</div>
              <div class="proc-type">Interventional Radiology</div>
              <div class="proc-name">Uterine Artery Embolisation (UAE)</div>
              <div class="proc-desc">Bilateral embolisation of uterine arteries via femoral or radial artery approach.
                Polyvinyl alcohol (PVA) or gelatin sponge particles. Fibroid infarction → volume reduction 40–60%. NICE
                NG88: recommended alternative to surgery for symptomatic fibroids. Post-embolisation syndrome: fever,
                pain,
                leucocytosis (3–5 days). Success rate: 80–90% symptom improvement. Not recommended if planning pregnancy
                (relative CI).</div>
              <div style="margin-top:10px;"><span class="badge badge-amber">Uterus Preserved</span></div>
            </div>
            <div class="proc-item">
              <div class="proc-dot">📡</div>
              <div class="proc-type">Energy-based / Ablation</div>
              <div class="proc-name">Radiofrequency Ablation &amp; MRgFUS</div>
              <div class="proc-desc"><strong>Acessa (laparoscopic RFA):</strong> USS-guided RFA probe placed into
                fibroid;
                thermal coagulation. Day case. Fibroid volume reduction ~40–50% at 12 months. <br><strong>Sonata
                  (transcervical RFA):</strong> Intrauterine sonication — for submucosal and intramural. No abdominal
                incision. <br><strong>MRgFUS / ExAblate:</strong> MRI-guided focused ultrasound — non-invasive, thermal
                ablation. Precise targeting. Not widely available. Fibroids must have specific MRI characteristics (low
                T2
                signal).</div>
              <div style="margin-top:10px;"><span class="badge badge-amber">Uterus Preserved</span></div>
            </div>
          </div>

          <div class="card reveal" style="margin-top:60px;">
            <div class="section-label" style="margin-bottom:16px;">Hysterectomy — Definitive Treatment</div>
            <div style="display:grid;grid-template-columns:1fr 1fr 1fr;gap:24px;font-size:0.85rem;">
              <div>
                <p
                  style="color:var(--pink);font-family:var(--font-mono);font-size:11px;letter-spacing:0.1em;text-transform:uppercase;margin-bottom:10px;">
                  Routes</p>
                <ul style="list-style:none;color:var(--text-2);">
                  <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Total laparoscopic hysterectomy
                    (TLH) —
                    preferred where feasible</li>
                  <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Vaginal hysterectomy — if uterus
                    small/mobile; no bowel/bladder involvement</li>
                  <li style="padding:5px 0;">Abdominal (TAH) — large uteri, complex adhesions</li>
                </ul>
              </div>
              <div>
                <p
                  style="color:var(--pink);font-family:var(--font-mono);font-size:11px;letter-spacing:0.1em;text-transform:uppercase;margin-bottom:10px;">
                  Indications</p>
                <ul style="list-style:none;color:var(--text-2);">
                  <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Completed family, failed/declined
                    all
                    alternatives</li>
                  <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Uterus too large / fibroids too
                    numerous for myomectomy</li>
                  <li style="padding:5px 0;">Emergency haemorrhage unresponsive to conservative measures</li>
                </ul>
              </div>
              <div>
                <p
                  style="color:var(--pink);font-family:var(--font-mono);font-size:11px;letter-spacing:0.1em;text-transform:uppercase;margin-bottom:10px;">
                  Key Points</p>
                <ul style="list-style:none;color:var(--text-2);">
                  <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Only definitive cure — no
                    recurrence
                    possible</li>
                  <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Ovarian conservation generally
                    recommended in premenopausal women (bilateral salpingo-oophorectomy not routine)</li>
                  <li style="padding:5px 0;border-bottom:1px solid var(--border-2);">Subtotal hysterectomy (cervix
                    retained) → less invasive, no risk of vaginal vault prolapse; requires ongoing smears</li>
                  <li style="padding:5px 0;">FDA 2014: power morcellation contraindicated in unsuspected LMS risk —
                    contained morcellation systems preferred</li>
                </ul>
              </div>
            </div>
          </div>
        </div>
      </details>

      <!-- India Procedures Context -->
      <details class="collapse-panel reveal" style="border-color:rgba(255,183,77,0.3);">
        <summary style="color:var(--amber);">🇮🇳 India — Procedure Availability <span class="collapse-hint">click to
            expand</span></summary>
        <div class="collapse-content">
          <div style="display:grid;grid-template-columns:1fr 1fr;gap:16px;font-size:0.82rem;color:var(--text-2);">
            <ul style="list-style:none;">
              <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">• Hysteroscopic myomectomy: available
                at
                tertiary centres <span class="india-badge limited">Tertiary</span></li>
              <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">• Laparoscopic myomectomy: increasingly
                available, FOGSI/MIS training workshops <span class="india-badge limited">Training ↑</span></li>
              <li style="padding:4px 0;">• <strong style="color:var(--text-1);">Abdominal myomectomy: most common
                  surgical
                  approach in India</strong> for large/multiple fibroids <span class="india-badge available">Widely
                  available</span></li>
            </ul>
            <ul style="list-style:none;">
              <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">• UAE: limited to select centres (AIIMS
                Delhi, CMC Vellore, Tata Memorial) <span class="india-badge limited">Tertiary IR</span></li>
              <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">• MRgFUS / RFA: very limited; mostly
                research settings <span class="india-badge unavailable">Research</span></li>
              <li style="padding:4px 0;">• <strong style="color:var(--text-1);">Hysterectomy: most commonly performed
                  major gynae surgery in India</strong> — TAH predominates, TLH growing <span
                  class="india-badge available">Universal</span></li>
            </ul>
          </div>
        </div>
      </details>
    </div>
  </section>

  <!-- ============================================================
     SECTION 12 — EMERGENCY
     ============================================================ -->
  <section id="emergency" aria-label="Emergency management">
    <div class="container">
      <div class="emergency-header reveal">
        <div class="emergency-pulse">🚨</div>
        <div>
          <div class="emergency-title">Acute Heavy Haemorrhage</div>
          <p style="color:var(--text-2);font-size:0.9rem;">Emergency scenario: fibroid-related life-threatening uterine
            bleeding</p>
        </div>
      </div>

      <details class="collapse-panel reveal">
        <summary>Emergency Protocol — Steps 01–04 <span class="collapse-hint">click to expand</span></summary>
        <div class="collapse-content">
          <div class="emergency-steps">
            <div class="emstep">
              <div class="emstep-num">01</div>
              <h4>Resuscitation (ABC)</h4>
              <ul>
                <li>Airway — maintain, O₂ 15L non-rebreathe mask</li>
                <li>2× large-bore IV access (14–16G antecubital)</li>
                <li>IV crystalloid (1L 0.9% NaCl bolus)</li>
                <li>Blood transfusion: O-negative if immediate, group-specific when available</li>
                <li>FBC, clotting, U&amp;E, Group &amp; Save / Cross-match 4 units</li>
                <li>Activate major haemorrhage protocol if Hb &lt;7 or haemodynamic instability</li>
                <li>Urinary catheter + hourly urine output monitoring</li>
              </ul>
            </div>
            <div class="emstep">
              <div class="emstep-num">02</div>
              <h4>Medical Control</h4>
              <ul>
                <li>IV Tranexamic acid 1g over 10 min STAT → can repeat at 30 min if ongoing</li>
                <li>High-dose progestogen: norethisterone 5mg TDS (oral if able)</li>
                <li>IV/IM Oxytocin 10 units (uterotonic — increases myometrial tone)</li>
                <li>Consider ergometrine / carboprost if needed</li>
                <li>Foley catheter balloon tamponade — intrauterine balloon inflated in cavity (if submucosal fibroid
                  accessible)</li>
                <li>Correct coagulopathy: FFP, cryoprecipitate, platelets as per haematology guidance (massive
                  transfusion
                  protocol)</li>
              </ul>
            </div>
            <div class="emstep">
              <div class="emstep-num">03</div>
              <h4>Procedural / Interventional</h4>
              <ul>
                <li>Emergency hysteroscopic myomectomy: if submucosal fibroid accessible and bleeding localised — resect
                  /
                  coagulate</li>
                <li>UAE (Uterine Artery Embolisation): if haemodynamically stable and IR team available — highly
                  effective;
                  bilateral femoral approach, immediate arterial occlusion</li>
                <li>Balloon uterine tamponade (e.g., Bakri balloon) — temporising measure while definitive treatment
                  arranged</li>
                <li>Uterine compression sutures (B-Lynch) — in theatre if proceeding to open surgery</li>
              </ul>
            </div>
            <div class="emstep">
              <div class="emstep-num">04</div>
              <h4>Surgical Escalation</h4>
              <ul>
                <li>Emergency hysterectomy: last resort when all else fails; life-saving</li>
                <li>Bilateral uterine artery ligation (open): temporising, fertility-sparing alternative to hysterectomy
                </li>
                <li>Internal iliac artery ligation: rarely performed; requires vascular surgical expertise</li>
                <li>Post-operative ICU admission if significant haemorrhage / coagulopathy</li>
                <li>Counsel: if hysterectomy performed, document discussions and emergency nature clearly</li>
                <li>Debrief patient and family post-crisis</li>
              </ul>
            </div>
          </div>

        </div>
      </details>

      <details class="collapse-panel reveal" style="border-color:rgba(239,83,80,0.2);">
        <summary style="color:var(--red);">Special Scenario — Torsion of Pedunculated Fibroid <span
            class="collapse-hint">click to expand</span></summary>
        <div class="collapse-content">
          <p style="font-size:0.85rem;color:var(--text-2);line-height:1.8;">
            Presents as acute abdomen — sudden-onset severe pelvic pain, nausea/vomiting, peritonism. USS: adnexal mass
            with absent/impaired Doppler flow in stalk. Often initially mistaken for ovarian torsion. Management:
            emergency laparoscopy / laparotomy → detorsion and myomectomy (or hysterectomy). If stalk necrosed, resect
            fibroid with stalk. No medical temporisation indicated.
          </p>
        </div>
      </details>

      <!-- Indian Emergency Context -->
      <details class="collapse-panel reveal" style="border-color:rgba(255,183,77,0.3);">
        <summary style="color:var(--amber);">🇮🇳 Indian Emergency Context <span class="collapse-hint">click to
            expand</span></summary>
        <div class="collapse-content">
          <ul style="list-style:none;font-size:0.82rem;color:var(--text-2);">
            <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">• <strong
                style="color:var(--amber);">Blood
                bank access:</strong> Challenges in rural/semi-urban areas — whole blood may be used if component
              therapy
              unavailable</li>
            <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">• <strong
                style="color:var(--amber);">Misoprostol PR 800mcg:</strong> Consider as uterotonic alternative if IV
              access delayed (widely available, ₹10–15/dose)</li>
            <li style="padding:4px 0;border-bottom:1px solid var(--border-2);">• <strong style="color:var(--amber);">IR
                for UAE:</strong> May require transfer to tertiary centre — plan for stabilisation + transfer if needed
            </li>
            <li style="padding:4px 0;">• Uterotonics universally available: oxytocin, ergometrine, carboprost</li>
          </ul>
        </div>
      </details>
    </div>
  </section>

  <!-- ============================================================
     SECTION 13 — EXAM PEARLS
     ============================================================ -->
  <section id="pearls" aria-label="High-yield exam pearls">
    <div class="orb orb-1" style="top:10%;right:-10%;opacity:0.1;"></div>
    <div class="container">
      <p class="section-label reveal">13 — High-Yield</p>
      <h2 class="section-title reveal">Exam <em>Pearls</em></h2>
      <p class="lead reveal">Click each pearl to reveal the full explanation. These are the highest-frequency exam
        topics on uterine fibroids in USMLE, MRCP/MRCOG, and medical school finals.</p>

      <div class="pearl-list reveal" id="pearlList">

        <div class="pearl-item">
          <div class="pearl-header" onclick="togglePearl(this)">
            <div class="pearl-num">01</div>
            <div class="pearl-question">What is the single most common benign tumour of the female pelvis?</div>
            <div class="pearl-toggle">+</div>
          </div>
          <div class="pearl-body">
            <div class="pearl-answer"><strong>Uterine leiomyoma (fibroid).</strong> Affects 70% of women by age 50
              globally; 24–30% in Indian women of reproductive age (JOGI). Most common cause of hysterectomy — the
              most performed major gynaecological surgery in India.</div>
          </div>
        </div>

        <div class="pearl-item">
          <div class="pearl-header" onclick="togglePearl(this)">
            <div class="pearl-num">02</div>
            <div class="pearl-question">Do fibroids undergo malignant transformation into leiomyosarcoma?</div>
            <div class="pearl-toggle">+</div>
          </div>
          <div class="pearl-body">
            <div class="pearl-answer"><strong>No — this is a classic myth.</strong> Leiomyosarcoma (LMS) arises <em>de
                novo</em> from myometrium, not from pre-existing fibroids. They are molecularly distinct entities. The
              probability of an apparent fibroid being LMS is ~1 in 350–500. Red flags: rapid growth (especially
              post-menopausal), irregular MRI margins, central necrosis, restricted diffusion on DWI. No reliable
              pre-operative test can exclude LMS.</div>
          </div>
        </div>

        <div class="pearl-item">
          <div class="pearl-header" onclick="togglePearl(this)">
            <div class="pearl-num">03</div>
            <div class="pearl-question">Which fibroid types are most associated with infertility and AUB?</div>
            <div class="pearl-toggle">+</div>
          </div>
          <div class="pearl-body">
            <div class="pearl-answer"><strong>Submucosal fibroids — FIGO Types 0, 1, and 2</strong> are most strongly
              associated with both abnormal uterine bleeding and infertility. They distort or contact the endometrial
              cavity, disrupting implantation, local haemostasis, and uterine contractility. Type 0 (pedunculated
              intracavitary) is fully accessible hysteroscopically. Type 3 (contacts endometrium, no visual distortion)
              may also impair implantation — important in IVF context.</div>
          </div>
        </div>

        <div class="pearl-item">
          <div class="pearl-header" onclick="togglePearl(this)">
            <div class="pearl-num">04</div>
            <div class="pearl-question">What happens to fibroids after menopause? What is the key exception?</div>
            <div class="pearl-toggle">+</div>
          </div>
          <div class="pearl-body">
            <div class="pearl-answer"><strong>Fibroids regress post-menopause</strong> due to the hypoestrogenic state.
              They often calcify ("womb stones"). Symptoms resolve. Therefore, asymptomatic or mildly symptomatic
              fibroids near menopause can often be managed expectantly. <strong>Exception:</strong> Women on HRT
              (especially oestrogen-only) may not see regression, and fibroids may continue to grow. A new or growing
              post-menopausal fibroid NOT on HRT should raise suspicion for LMS.</div>
          </div>
        </div>

        <div class="pearl-item">
          <div class="pearl-header" onclick="togglePearl(this)">
            <div class="pearl-num">05</div>
            <div class="pearl-question">What is red degeneration? When does it occur and how is it managed?</div>
            <div class="pearl-toggle">+</div>
          </div>
          <div class="pearl-body">
            <div class="pearl-answer"><strong>Red (carneous) degeneration</strong> occurs in pregnancy — typically 2nd
              trimester. The fibroid undergoes acute haemorrhagic infarction as rapidly increasing pregnancy hormones
              drive growth faster than blood supply can sustain. Features: sudden-onset severe localised uterine
              tenderness (fibroid site), low-grade pyrexia, leucocytosis, raised CRP. USS: heterogeneous fibroid
              echogenicity. <strong>Management: conservative</strong> — analgesia (paracetamol, opioids if severe), IV
              fluids, hydration. NSAIDs may be used before 28 weeks. Self-limiting — no surgery required. Fetal outcome
              generally good if managed appropriately.</div>
          </div>
        </div>

        <div class="pearl-item">
          <div class="pearl-header" onclick="togglePearl(this)">
            <div class="pearl-num">06</div>
            <div class="pearl-question">What is the status of ulipristal acetate (Esmya) for fibroids?</div>
            <div class="pearl-toggle">+</div>
          </div>
          <div class="pearl-body">
            <div class="pearl-answer"><strong>Ulipristal acetate (UPA) is currently SUSPENDED</strong> in Europe and the
              UK as of 2020. The EMA suspended marketing authorisation for Esmya following post-marketing reports of
              serious hepatotoxicity, including liver failure requiring transplantation. The risk-benefit balance was
              deemed unfavourable. In exams: know it as an SPRM that was formerly used for fibroid treatment but is no
              longer recommended due to liver toxicity. Do not recommend it in clinical scenarios.</div>
          </div>
        </div>

        <div class="pearl-item">
          <div class="pearl-header" onclick="togglePearl(this)">
            <div class="pearl-num">07</div>
            <div class="pearl-question">What are the rules for GnRH agonist use in fibroid management?</div>
            <div class="pearl-toggle">+</div>
          </div>
          <div class="pearl-body">
            <div class="pearl-answer"><strong>Key rules:</strong> (1) Maximum 3–6 months — bone density loss beyond this
              is clinically significant and potentially irreversible. (2) Always prescribe add-back HRT (low-dose
              oestrogen ± progestogen) if using beyond 3 months — prevents hypoestrogenic side effects without negating
              efficacy. (3) There is an initial "flare" in the first 1–2 weeks (gonadotrophin surge before pituitary
              desensitisation) — cover with progestogen or barrier method initially. (4) Fibroids regrow within 3–6
              months of stopping — not curative; used pre-operatively. (5) Useful to improve anaemia before surgery and
              reduce uterine size to enable laparoscopic/vaginal approach.</div>
          </div>
        </div>

        <div class="pearl-item">
          <div class="pearl-header" onclick="togglePearl(this)">
            <div class="pearl-num">08</div>
            <div class="pearl-question">Is UAE safe if a woman wants to get pregnant in future?</div>
            <div class="pearl-toggle">+</div>
          </div>
          <div class="pearl-body">
            <div class="pearl-answer"><strong>UAE is a relative contraindication if future pregnancy strongly
                desired.</strong> Concerns include: ovarian reserve reduction (non-target embolisation of ovarian
              collateral vessels), uterine artery occlusion limiting placental perfusion, increased miscarriage risk,
              preterm birth, malpresentation, and PPH. NICE NG88 (2018) states UAE should be discussed as an option even
              in women who wish to preserve fertility, with full counselling about the risks. ACOG advises myomectomy as
              preferred fertility-preserving surgical option. There are successful pregnancies after UAE, but data is
              inferior to post-myomectomy outcomes.</div>
          </div>
        </div>

        <div class="pearl-item">
          <div class="pearl-header" onclick="togglePearl(this)">
            <div class="pearl-num">09</div>
            <div class="pearl-question">What is the most common somatic mutation in uterine fibroids?</div>
            <div class="pearl-toggle">+</div>
          </div>
          <div class="pearl-body">
            <div class="pearl-answer"><strong>MED12 mutation</strong> — present in approximately 70% of uterine
              leiomyomas. Affects exon 2 of the Mediator complex subunit 12 gene, which regulates RNA polymerase II
              transcription. This is the most common somatic driver mutation. HMGA2 rearrangements are next (~20%). The
              rare <strong>FH (fumarate hydratase) germline mutation</strong> causes hereditary leiomyomatosis and renal
              cell carcinoma (HLRCC) — presents with multiple, aggressive fibroids in young women; should prompt genetic
              testing and renal surveillance.</div>
          </div>
        </div>

        <div class="pearl-item">
          <div class="pearl-header" onclick="togglePearl(this)">
            <div class="pearl-num">10</div>
            <div class="pearl-question">Name the FIGO PALM-COEIN classification of AUB and where fibroids fit.</div>
            <div class="pearl-toggle">+</div>
          </div>
          <div class="pearl-body">
            <div class="pearl-answer"><strong>PALM-COEIN</strong> classifies causes of AUB: <strong>P</strong>olyp ·
              <strong>A</strong>denomyosis · <strong>L</strong>eiomyoma · <strong>M</strong>alignancy &amp; Hyperplasia
              — structural causes | <strong>C</strong>oagulopathy · <strong>O</strong>vulatory dysfunction ·
              <strong>E</strong>ndometrial · <strong>I</strong>atrogenic · <strong>N</strong>ot yet classified —
              non-structural causes. Fibroids are the "L". The fibroid can be subclassified using FIGO Types 0–8 to
              specify its relationship to the endometrium (critical for treatment planning). AUB-L is most clinically
              significant when the fibroid is submucosal (Types 0–3).
            </div>
          </div>
        </div>

        <div class="pearl-item">
          <div class="pearl-header" onclick="togglePearl(this)">
            <div class="pearl-num">11</div>
            <div class="pearl-question">What are the obstetric complications of fibroids and which fibroid type causes
              them?</div>
            <div class="pearl-toggle">+</div>
          </div>
          <div class="pearl-body">
            <div class="pearl-answer">Fibroids in pregnancy increase risk of: <strong>miscarriage</strong> (submucosal,
              especially if implantation occurs over fibroid); <strong>preterm labour</strong> (uterine irritability);
              <strong>malpresentation</strong> (distorted cavity/lower segment fibroids); <strong>placenta
                praevia</strong> (lower segment fibroid); <strong>placental abruption</strong> (retroplacental fibroid);
              <strong>PPH</strong> (impaired uterine contraction); <strong>CS delivery</strong>; <strong>red
                degeneration</strong> (pregnancy-specific). Posterior and lower segment fibroids pose greatest obstetric
              risk. Fibroids may enlarge in first trimester then regress in third trimester.
            </div>
          </div>
        </div>

        <div class="pearl-item">
          <div class="pearl-header" onclick="togglePearl(this)">
            <div class="pearl-num">12</div>
            <div class="pearl-question">When should LNG-IUS (Mirena) NOT be used for fibroid-related AUB?</div>
            <div class="pearl-toggle">+</div>
          </div>
          <div class="pearl-body">
            <div class="pearl-answer"><strong>LNG-IUS is contraindicated when the endometrial cavity is significantly
                distorted</strong> by submucosal fibroids. A distorted cavity makes insertion difficult or impossible,
              increases expulsion rate, and may prevent the device from releasing levonorgestrel effectively. A TVUSS or
              SIS should be performed before insertion to assess cavity. If FIGO Types 0–2 are present with significant
              cavity distortion, treat the fibroid first (hysteroscopic myomectomy), then insert LNG-IUS. Also
              contraindicated: unexplained AUB (exclude malignancy first), active PID, pregnancy.</div>
          </div>
        </div>

      </div>
    </div>
  </section>

  <!-- ============================================================
     SECTION 14 — QUIZ
     ============================================================ -->
  <section id="quiz" aria-label="Self-assessment quiz">
    <div class="container">
      <p class="section-label reveal">14 — Self-Assessment</p>
      <h2 class="section-title reveal">Test Your <em>Knowledge</em></h2>
      <p class="lead reveal" style="margin-bottom:48px;">Five high-yield MCQs. Click an answer to receive immediate
        feedback and explanation.</p>

      <div class="quiz-container reveal">
        <div class="quiz-progress" id="quizProgress">
          <div class="quiz-progress-dot active"></div>
          <div class="quiz-progress-dot"></div>
          <div class="quiz-progress-dot"></div>
          <div class="quiz-progress-dot"></div>
          <div class="quiz-progress-dot"></div>
        </div>

        <div id="quizQuestions">
          <!-- Q1 -->
          <div class="quiz-q" id="q0">
            <div class="quiz-question-num">Question 1 of 5</div>
            <div class="quiz-question">A 38-year-old woman presents with heavy menstrual bleeding. Pelvic USS reveals a
              3.5cm fibroid that is entirely within the endometrial cavity on a stalk. What is the FIGO classification?
            </div>
            <div class="quiz-options">
              <div class="quiz-option" onclick="answerQ(0,0,false)"><span class="quiz-opt-letter">A</span> FIGO Type 1
              </div>
              <div class="quiz-option" onclick="answerQ(0,1,true)"><span class="quiz-opt-letter">B</span> FIGO Type 0
              </div>
              <div class="quiz-option" onclick="answerQ(0,2,false)"><span class="quiz-opt-letter">C</span> FIGO Type 3
              </div>
              <div class="quiz-option" onclick="answerQ(0,3,false)"><span class="quiz-opt-letter">D</span> FIGO Type 4
              </div>
            </div>
            <div class="quiz-explanation" id="exp0">
              <strong>B — FIGO Type 0</strong> is correct. Type 0 = pedunculated intracavitary fibroid — entirely within
              the endometrial cavity on a stalk, with no intramural component. This is the most favourable type for
              hysteroscopic myomectomy, achievable as a single-stage procedure. Type 1 = submucosal with &lt;50%
              intramural extension. Type 3 = contacts but does not distort the endometrium. Type 4 = entirely
              intramural.
            </div>
          </div>

          <!-- Q2 -->
          <div class="quiz-q" id="q1" style="display:none;">
            <div class="quiz-question-num">Question 2 of 5</div>
            <div class="quiz-question">A 42-year-old has large symptomatic fibroids and wishes to preserve her uterus
              but has completed her family. She is medically fit. NICE NG88 recommends which intervention as a primary
              alternative to hysterectomy?</div>
            <div class="quiz-options">
              <div class="quiz-option" onclick="answerQ(1,0,false)"><span class="quiz-opt-letter">A</span> GnRH agonist
                therapy long-term</div>
              <div class="quiz-option" onclick="answerQ(1,1,false)"><span class="quiz-opt-letter">B</span> Ulipristal
                acetate (Esmya)</div>
              <div class="quiz-option" onclick="answerQ(1,2,true)"><span class="quiz-opt-letter">C</span> Uterine Artery
                Embolisation (UAE)</div>
              <div class="quiz-option" onclick="answerQ(1,3,false)"><span class="quiz-opt-letter">D</span> Endometrial
                ablation</div>
            </div>
            <div class="quiz-explanation" id="exp1">
              <strong>C — UAE</strong> is correct. NICE NG88 (2018) recommends UAE as an effective, recommended
              alternative to surgery (hysterectomy/myomectomy) for women with symptomatic fibroids. GnRH agonists are
              not suitable long-term (bone loss). Ulipristal acetate is <strong>suspended</strong> due to
              hepatotoxicity. Endometrial ablation does not treat fibroids themselves and is contraindicated if cavity
              is distorted.
            </div>
          </div>

          <!-- Q3 -->
          <div class="quiz-q" id="q2" style="display:none;">
            <div class="quiz-question-num">Question 3 of 5</div>
            <div class="quiz-question">A 28-year-old woman at 20 weeks gestation presents with sudden-onset severe
              left-sided uterine pain, low-grade fever (37.8°C), and leucocytosis. A fibroid is visible on USS with
              heterogeneous echogenicity. Fetal heart is present. What is the most likely diagnosis and management?
            </div>
            <div class="quiz-options">
              <div class="quiz-option" onclick="answerQ(2,0,false)"><span class="quiz-opt-letter">A</span> Torsion of
                pedunculated fibroid — emergency laparoscopy</div>
              <div class="quiz-option" onclick="answerQ(2,1,true)"><span class="quiz-opt-letter">B</span> Red (carneous)
                degeneration — conservative management</div>
              <div class="quiz-option" onclick="answerQ(2,2,false)"><span class="quiz-opt-letter">C</span> Acute
                appendicitis — surgical consult</div>
              <div class="quiz-option" onclick="answerQ(2,3,false)"><span class="quiz-opt-letter">D</span> Placental
                abruption — immediate delivery</div>
            </div>
            <div class="quiz-explanation" id="exp2">
              <strong>B — Red degeneration</strong> is correct. This is the classic presentation: pregnancy (typically
              2nd trimester), localised uterine tenderness over the fibroid site, low-grade fever, leucocytosis. The
              fibroid undergoes haemorrhagic infarction as blood supply cannot match growth stimulated by pregnancy
              hormones. Management is <strong>conservative</strong>: analgesia, IV fluids, hydration. It is
              self-limiting. Surgery is NOT indicated. This is a high-yield differentiating point from torsion (acute
              abdomen, usually non-pregnant patient) and appendicitis (RIF pain, different tenderness pattern).
            </div>
          </div>

          <!-- Q4 -->
          <div class="quiz-q" id="q3" style="display:none;">
            <div class="quiz-question-num">Question 4 of 5</div>
            <div class="quiz-question">Which single genetic mutation is most commonly identified in uterine leiomyomas?
            </div>
            <div class="quiz-options">
              <div class="quiz-option" onclick="answerQ(3,0,false)"><span class="quiz-opt-letter">A</span> BRCA1</div>
              <div class="quiz-option" onclick="answerQ(3,1,false)"><span class="quiz-opt-letter">B</span> HMGA2
                rearrangement</div>
              <div class="quiz-option" onclick="answerQ(3,2,true)"><span class="quiz-opt-letter">C</span> MED12 mutation
                (exon 2)</div>
              <div class="quiz-option" onclick="answerQ(3,3,false)"><span class="quiz-opt-letter">D</span> TP53 mutation
              </div>
            </div>
            <div class="quiz-explanation" id="exp3">
              <strong>C — MED12 mutation</strong> is correct, present in approximately 70% of uterine leiomyomas.
              Specifically affects exon 2 of the Mediator complex subunit 12 gene. HMGA2 rearrangements are the second
              most common (~20%). BRCA1 is associated with breast/ovarian cancer. TP53 mutations are associated with
              malignancy (leiomyosarcoma, not leiomyoma). The rare FH (fumarate hydratase) germline mutation causes
              hereditary leiomyomatosis and renal cell carcinoma (HLRCC) — aggressive fibroids in young women, requires
              renal surveillance.
            </div>
          </div>

          <!-- Q5 -->
          <div class="quiz-q" id="q4" style="display:none;">
            <div class="quiz-question-num">Question 5 of 5</div>
            <div class="quiz-question">A post-menopausal woman (58 years old, NOT on HRT) presents with a new pelvic
              mass that has grown rapidly over 6 months. Ultrasound shows a large heterogeneous uterine mass with
              irregular margins and central areas of low echogenicity. What is the most important concern and initial
              investigation?</div>
            <div class="quiz-options">
              <div class="quiz-option" onclick="answerQ(4,0,false)"><span class="quiz-opt-letter">A</span> New fibroid —
                annual USS surveillance</div>
              <div class="quiz-option" onclick="answerQ(4,1,false)"><span class="quiz-opt-letter">B</span> Adenomyosis —
                MRI pelvis for confirmation</div>
              <div class="quiz-option" onclick="answerQ(4,2,true)"><span class="quiz-opt-letter">C</span> Leiomyosarcoma
                — urgent MRI pelvis and surgical referral</div>
              <div class="quiz-option" onclick="answerQ(4,3,false)"><span class="quiz-opt-letter">D</span> Ovarian
                carcinoma — CA-125 and CT chest/abdomen/pelvis</div>
            </div>
            <div class="quiz-explanation" id="exp4">
              <strong>C — Leiomyosarcoma (LMS)</strong> must be urgently excluded. Red flags present: post-menopausal
              woman NOT on HRT (fibroids regress post-menopause), <strong>rapid growth</strong>, heterogeneous
              echogenicity, irregular margins suggesting malignancy. <strong>MRI pelvis</strong> is the gold standard —
              LMS: heterogeneous high T2 signal, central necrosis, restricted diffusion on DWI. However, no imaging
              reliably excludes LMS pre-operatively — surgical removal and histological assessment is ultimately
              required. Surgical referral to a gynaecological oncologist is appropriate. Remember: LMS does NOT arise
              from malignant transformation of benign fibroids.
            </div>
          </div>
        </div>

        <div class="quiz-score" id="quizScore">
          <div class="score-number" id="scoreNumber">0/5</div>
          <div class="score-label" id="scoreLabel">Loading score...</div>
          <div style="margin-top:32px;">
            <button class="btn btn-primary" onclick="resetQuiz()">Retake Quiz</button>
          </div>
        </div>

        <div class="quiz-nav" id="quizNav">
          <span style="font-size:0.8rem;color:var(--text-3);font-family:var(--font-mono);">select an answer to
            continue</span>
        </div>
      </div>
    </div>
  </section>

  <!-- ============================================================
     SECTION — SUMMARY / TAKE-HOME POINTS
     ============================================================ -->
  <section id="summary" aria-label="Summary">
    <div class="container">
      <p class="section-label reveal">Key Take-Home Points</p>
      <h2 class="section-title reveal">Summary & <em>Conclusions</em></h2>
      <div class="grid-2 reveal" style="margin-top:32px;">
        <div>
          <ol style="list-style:none;counter-reset:summary;">
            <li
              style="padding:12px 0;border-bottom:1px solid var(--border-2);font-size:0.95rem;color:var(--text-2);line-height:1.7;">
              <strong style="color:var(--purple);margin-right:8px;">1.</strong>
              Fibroids are the <strong style="color:var(--text-1);">most common benign pelvic tumour</strong> —
              affecting up to 70% of women by age 50. Most are asymptomatic.
            </li>
            <li
              style="padding:12px 0;border-bottom:1px solid var(--border-2);font-size:0.95rem;color:var(--text-2);line-height:1.7;">
              <strong style="color:var(--purple);margin-right:8px;">2.</strong>
              <strong style="color:var(--text-1);">Oestrogen + progesterone</strong> drive growth. Fibroids regress
              post-menopause. Key mutations: MED12 (70%), HMGA2, FH.
            </li>
            <li
              style="padding:12px 0;border-bottom:1px solid var(--border-2);font-size:0.95rem;color:var(--text-2);line-height:1.7;">
              <strong style="color:var(--purple);margin-right:8px;">3.</strong>
              <strong style="color:var(--text-1);">FIGO classification (0–8)</strong> determines management. Submucosal
              (Type 0–2) → hysteroscopic; Intramural/Subserosal → lap/open myomectomy or UAE.
            </li>
            <li
              style="padding:12px 0;border-bottom:1px solid var(--border-2);font-size:0.95rem;color:var(--text-2);line-height:1.7;">
              <strong style="color:var(--purple);margin-right:8px;">4.</strong>
              <strong style="color:var(--text-1);">USS is first-line</strong> investigation. MRI is gold standard for
              mapping. Saline infusion sonography for submucosal assessment.
            </li>
          </ol>
        </div>
        <div>
          <ol style="list-style:none;">
            <li
              style="padding:12px 0;border-bottom:1px solid var(--border-2);font-size:0.95rem;color:var(--text-2);line-height:1.7;">
              <strong style="color:var(--purple);margin-right:8px;">5.</strong>
              <strong style="color:var(--text-1);">Medical management first-line:</strong> Tranexamic acid for acute
              bleeding, LNG-IUS (Mirena) for long-term, GnRH agonists pre-operatively to shrink fibroids.
            </li>
            <li
              style="padding:12px 0;border-bottom:1px solid var(--border-2);font-size:0.95rem;color:var(--text-2);line-height:1.7;">
              <strong style="color:var(--purple);margin-right:8px;">6.</strong>
              <strong style="color:var(--text-1);">Hysterectomy is the only cure</strong> with zero recurrence.
              Myomectomy preserves fertility but has 15–30% recurrence rate.
            </li>
            <li
              style="padding:12px 0;border-bottom:1px solid var(--border-2);font-size:0.95rem;color:var(--text-2);line-height:1.7;">
              <strong style="color:var(--purple);margin-right:8px;">7.</strong>
              <strong style="color:var(--text-1);">LMS is de novo</strong> — NOT malignant transformation of fibroids.
              Power morcellation contraindicated (risk of disseminating occult sarcoma).
            </li>
            <li style="padding:12px 0;font-size:0.95rem;color:var(--text-2);line-height:1.7;">
              <strong style="color:var(--purple);margin-right:8px;">8.</strong>
              <strong style="color:var(--text-1);">Red degeneration in pregnancy</strong> — manage conservatively with
              analgesics and hydration. Avoid surgery unless torsion of pedunculated fibroid.
            </li>
          </ol>
        </div>
      </div>
    </div>
  </section>

  <!-- ============================================================
     SECTION 15 — REFERENCES
     ============================================================ -->
  <section id="references" aria-label="References and guidelines">
    <div class="container">
      <p class="section-label reveal">15 — References</p>
      <h2 class="section-title reveal">Guidelines &amp; <em>Sources</em></h2>

      <div class="country-note reveal">
        <h4>⚠️ International Guideline Variation</h4>
        <p><strong>UK (NICE NG88, 2018):</strong> Recommends UAE as an evidence-based alternative to surgery; LNG-IUS as
          first-line medical; ulipristal acetate was recommended (now suspended). Myomectomy for fertility preservation.
          Hysterectomy for definitive management.</p>
        <p style="margin-top:8px;"><strong>USA (ACOG Practice Bulletin 228, 2021):</strong> Similar framework; GnRH
          agonist pre-operatively widely used; elagolix/relugolix approved (Oriahnn, Myfembree) — may not be available
          in UK. Power morcellation banned except in containment bags (FDA 2020).</p>
        <p style="margin-top:8px;"><strong>Australia/NZ (RANZCOG):</strong> Broadly aligned with NICE; UAE available but
          access more limited in some centres. Relugolix/elagolix not yet TGA-approved at time of writing.</p>
        <p style="margin-top:8px;"><strong>Europe (ESHRE/ESGE):</strong> Hysteroscopic myomectomy classification and
          operative difficulty scoring (ESGE) widely used in Europe. UPA suspended across EU (EMA 2020).</p>
        <p style="margin-top:8px;"><strong>India (FOGSI):</strong> FOGSI guidelines emphasise stepwise medical
          management before surgical intervention. GnRH agonists (leuprolide) widely available. Drug cost and access
          influence treatment choice — relugolix/elagolix not yet widely available. UAE offered at tertiary centres.
          Mifepristone studied extensively in Indian trials for fibroid-related symptoms.</p>
      </div>

      <ul class="ref-list reveal">
        <li><span class="ref-num">[1]</span> Munro MG, Critchley HOD, Broder MS, Fraser IS; FIGO Working Group on
          Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in
          nongravid women of reproductive age. <em>Int J Gynaecol Obstet.</em> 2011;113(1):3–13.</li>
        <li><span class="ref-num">[2]</span> Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee. The
          two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal
          uterine bleeding in the reproductive years: 2018 revisions. <em>Int J Gynaecol Obstet.</em>
          2018;143(3):393–408.</li>
        <li><span class="ref-num">[3]</span> NICE. Heavy menstrual bleeding: assessment and management. NICE guideline
          NG88. Published January 2018, updated March 2021. National Institute for Health and Care Excellence, UK.</li>
        <li><span class="ref-num">[4]</span> ACOG Practice Bulletin No. 228: Management of symptomatic uterine
          leiomyomas. <em>Obstet Gynecol.</em> 2021;137(6):e100–e115.</li>
        <li><span class="ref-num">[5]</span> Stewart EA. Uterine fibroids. <em>Lancet.</em> 2001;357(9252):293–298.</li>
        <li><span class="ref-num">[6]</span> Makinen N, et al. MED12 exon 2 mutations are common in uterine leiomyomas.
          <em>Science.</em> 2011;334(6053):252–255.
        </li>
        <li><span class="ref-num">[7]</span> European Medicines Agency. Esmya (ulipristal acetate): suspension of
          marketing authorisations during ongoing EMA review. EMA press release, 12 March 2020.</li>
        <li><span class="ref-num">[8]</span> Al-Hendy A, Myers ER, Stewart E, et al. Treatment of uterine fibroid
          symptoms with relugolix combination therapy. LIBERTY 1 and LIBERTY 2 trials. <em>N Engl J Med.</em>
          2021;384(7):630–642.</li>
        <li><span class="ref-num">[9]</span> Laughlin-Tommaso SK. Alternatives to hysterectomy: management of uterine
          fibroids. <em>Obstet Gynecol Clin North Am.</em> 2016;43(3):397–413.</li>
        <li><span class="ref-num">[10]</span> Doherty L, et al. Leiomyomas and reproductive outcomes. <em>Best Pract Res
            Clin Obstet Gynaecol.</em> 2018;46:54–67.</li>
        <li><span class="ref-num">[11]</span> Kumar V, Abbas AK, Aster JC. <em>Robbins and Cotran Pathologic Basis of
            Disease.</em> 10th ed. Philadelphia: Elsevier; 2021. Chapter 22: Female Genital System and Breast.</li>
        <li><span class="ref-num">[12]</span> Mara M, et al. Midterm clinical and first reproductive results of a
          randomized controlled trial comparing uterine fibroid embolization and myomectomy. <em>Cardiovasc Intervent
            Radiol.</em> 2008;31(1):73–85.</li>
        <li><span class="ref-num">[13]</span> FOGSI GCPR on Leiomyoma Uterus. Federation of Obstetric & Gynaecological
          Societies of India. Good Clinical Practice Recommendations on Management of Leiomyoma. 2022.</li>
        <li><span class="ref-num">[14]</span> International Institute for Population Sciences (IIPS), ICF. National
          Family Health Survey (NFHS-5), 2019–21: India Fact Sheet. Mumbai: IIPS; 2022.</li>
      </ul>

      <div class="card reveal" style="margin-top:40px;text-align:center;">
        <p
          style="font-family:var(--font-mono);font-size:11px;color:var(--text-3);letter-spacing:0.12em;text-transform:uppercase;margin-bottom:8px;">
          Created for medical education</p>
        <p style="color:var(--text-2);font-size:0.85rem;">This presentation is intended for qualified medical students
          and educators. Clinical decisions should be made using current local guidelines and in consultation with
          appropriate specialists. Medical knowledge evolves — always verify against current guidelines.</p>
      </div>
    </div>
  </section>

  <footer>
    <div class="container">
      <p style="margin-bottom:8px;">Uterine Fibroids (Leiomyomas) — Interactive Medical Lecture · Clinically Accurate
      </p>
      <p style="font-size:0.72rem;color:var(--purple);opacity:0.7;letter-spacing:0.08em;">Built with love and care for
        furthering the standards in OB-GYN · <span style="color:var(--text-2);">Akash Stephen Labs</span> × <span
          style="color:var(--text-2);">Claude Code</span></p>
    </div>
  </footer>

  <!-- ============================================================
     JAVASCRIPT — INTERACTIONS, ANIMATIONS, QUIZ
     ============================================================ -->
  <script>
    gsap.registerPlugin(ScrollTrigger, ScrollToPlugin);

    // ---- SECTION CONFIGURATION ----
    const sections = [
      { id: 'hero', label: 'Introduction' },
      { id: 'epidemiology', label: 'Epidemiology' },
      { id: 'pathophysiology', label: 'Pathophysiology' },
      { id: 'classification', label: 'Classification' },
      { id: 'figo', label: 'FIGO Types' },
      { id: 'symptoms', label: 'Symptoms' },
      { id: 'complications', label: 'Complications' },
      { id: 'differential', label: 'Differentials' },
      { id: 'diagnosis', label: 'Diagnosis' },
      { id: 'management', label: 'Management' },
      { id: 'drugs', label: 'Drug Therapy' },
      { id: 'procedures', label: 'Procedures' },
      { id: 'emergency', label: 'Emergency' },
      { id: 'pearls', label: 'Exam Pearls' },
      { id: 'quiz', label: 'Quiz' },
      { id: 'summary', label: 'Summary' },
      { id: 'references', label: 'References' }
    ];

    // ---- DOT NAV ----
    const dotNav = document.getElementById('dot-nav');
    sections.forEach((s, i) => {
      const dot = document.createElement('button');
      dot.className = 'dot' + (i === 0 ? ' active' : '');
      dot.setAttribute('aria-label', s.label);
      dot.setAttribute('title', s.label);
      dot.innerHTML = `<span class="dot-label">${s.label}</span>`;
      dot.addEventListener('click', () => {
        gsap.to(window, { duration: 0.8, scrollTo: `#${s.id}`, ease: 'power2.inOut' });
      });
      dotNav.appendChild(dot);
    });

    // ---- PROGRESS BAR ----
    window.addEventListener('scroll', () => {
      const scrollTop = window.scrollY;
      const docHeight = document.body.scrollHeight - window.innerHeight;
      const pct = (scrollTop / docHeight) * 100;
      document.getElementById('progress-bar').style.width = pct + '%';
    });

    // ---- UPDATE ACTIVE DOT ----
    sections.forEach((s, i) => {
      ScrollTrigger.create({
        trigger: `#${s.id}`,
        start: 'top 60%',
        end: 'bottom 60%',
        onEnter: () => updateDot(i),
        onEnterBack: () => updateDot(i)
      });
    });
    function updateDot(i) {
      document.querySelectorAll('.dot').forEach((d, j) => {
        d.classList.toggle('active', j === i);
      });
    }

    // ---- HERO REVEAL ----
    gsap.fromTo('.hero-eyebrow', { opacity: 0, y: 30 }, { opacity: 1, y: 0, duration: 1, delay: 0.3 });
    gsap.fromTo('.hero-title .line-1', { opacity: 0, y: 50 }, { opacity: 1, y: 0, duration: 1, delay: 0.5 });
    gsap.fromTo('.hero-title .line-2', { opacity: 0, y: 50 }, { opacity: 1, y: 0, duration: 1, delay: 0.7 });
    gsap.fromTo('.hero-subtitle', { opacity: 0, y: 30 }, { opacity: 1, y: 0, duration: 1, delay: 0.9 });
    gsap.fromTo('.hero-tags', { opacity: 0, y: 20 }, { opacity: 1, y: 0, duration: 0.8, delay: 1.1 });
    gsap.fromTo('.hero-stat-row', { opacity: 0, y: 20 }, { opacity: 1, y: 0, duration: 0.8, delay: 1.3 });

    // ---- SCROLL REVEALS ----
    gsap.utils.toArray('.reveal').forEach(el => {
      gsap.fromTo(el, { opacity: 0, y: 40 }, {
        opacity: 1, y: 0, duration: 0.8,
        ease: 'power2.out',
        scrollTrigger: {
          trigger: el,
          start: 'top 85%',
          toggleActions: 'play none none none'
        }
      });
    });

    // ---- STAT COUNTERS ----
    function animateCounters() {
      document.querySelectorAll('[data-count]').forEach(el => {
        const target = parseInt(el.dataset.count);
        const suffix = el.dataset.suffix || '';
        ScrollTrigger.create({
          trigger: el,
          start: 'top 80%',
          once: true,
          onEnter: () => {
            let start = 0;
            const duration = 1500;
            const step = target / (duration / 16);
            const timer = setInterval(() => {
              start = Math.min(start + step, target);
              el.textContent = Math.floor(start) + suffix;
              if (start >= target) clearInterval(timer);
            }, 16);
          }
        });
      });
    }
    animateCounters();

    // ---- RACE BARS ----
    document.querySelectorAll('.race-bar-fill').forEach(bar => {
      ScrollTrigger.create({
        trigger: bar,
        start: 'top 90%',
        once: true,
        onEnter: () => {
          bar.style.width = bar.dataset.width + '%';
        }
      });
    });

    // ---- FIBROID TYPE EXPLORER ----
    const typeData = {
      intramural: {
        badge: '<span class="badge badge-purple">FIGO Types 4 (primary)</span>',
        title: 'Intramural Fibroid',
        body: 'Entirely within the myometrium, not distorting the endometrial cavity or serosal surface. The most common type (~70%). May enlarge significantly before becoming symptomatic.',
        items: [
          'Menorrhagia if large enough to disrupt endometrial vascular remodelling',
          'Pelvic heaviness and dysmenorrhoea with large fibroids',
          'Subfertility if cavity significantly distorted (FIGO Type 3 = contacts endometrium)',
          'Irregular, non-tender uterine enlargement on bimanual examination',
          'Management: medical first-line; laparoscopic/open myomectomy if symptomatic; UAE'
        ],
        svgShow: ['fib-im-1', 'fib-im-2'],
        svgHide: ['fib-sm-1', 'fib-ss-1', 'fib-ss-1', 'fib-ped-stalk', 'fib-ped-1', 'fib-cerv-1']
      },
      submucosal: {
        badge: '<span class="badge badge-pink">FIGO Types 0–3</span>',
        title: 'Submucosal Fibroid',
        body: 'Projects into or distorts the endometrial cavity. The most symptomatic type. Directly affects endometrial function, causing heavy bleeding and impaired implantation. Critical for infertility and AUB.',
        items: [
          'Menorrhagia — disrupts spiral arteriole haemostasis; most severe AUB of all types',
          'Infertility — impairs implantation, reduces IVF success rates (RR ~0.3 for live birth)',
          'Recurrent miscarriage — cavity distortion prevents normal embryo development',
          'Dysmenorrhoea — uterine cramping as cavity is distorted',
          'Management: hysteroscopic myomectomy (Types 0–2) — day case; GnRH agonist pre-treatment to reduce size'
        ],
        svgShow: ['fib-sm-1'],
        svgHide: ['fib-im-1', 'fib-im-2', 'fib-ss-1', 'fib-ped-stalk', 'fib-ped-1', 'fib-cerv-1']
      },
      subserosal: {
        badge: '<span class="badge badge-teal">FIGO Types 5–6</span>',
        title: 'Subserosal Fibroid',
        body: 'Projects from the outer (serosal) surface of the uterus, predominantly into the peritoneal cavity. Causes bulk symptoms. Does not directly affect the endometrial cavity (minimal bleeding).',
        items: [
          'Pelvic pressure / heaviness — large subserosal fibroids displace adjacent organs',
          'Urinary frequency and urgency — anterior fibroid compresses bladder',
          'Constipation and tenesmus — posterior fibroid compresses rectosigmoid',
          'Hydronephrosis — lateral fibroid compresses ureter (rare, chronic)',
          'Management: medical for symptoms; UAE; laparoscopic myomectomy for pedunculated/subserosal'
        ],
        svgShow: ['fib-ss-1'],
        svgHide: ['fib-im-1', 'fib-im-2', 'fib-sm-1', 'fib-ped-stalk', 'fib-ped-1', 'fib-cerv-1']
      },
      pedunculated: {
        badge: '<span class="badge badge-amber">FIGO Type 0 or 7</span>',
        title: 'Pedunculated Fibroid',
        body: 'Attached to the uterus by a stalk (pedicle). Can project into the endometrial cavity (submucosal pedunculated — FIGO Type 0) or externally (subserosal pedunculated — FIGO Type 7). Critical risk: torsion.',
        items: [
          'Torsion — stalk twists, causing acute abdomen; surgical emergency (laparoscopy/laparotomy)',
          'Intracavitary (Type 0): most favourable for hysteroscopic resection; complete resection in single stage',
          'Extracavitary (Type 7): can mimic ovarian mass on imaging — follow the stalk to uterus on USS/MRI',
          'Prolapse through cervical os — pedunculated submucosal fibroid may visibly prolapse; visible on speculum',
          'Management: hysteroscopic resection (Type 0); laparoscopic removal (Type 7)'
        ],
        svgShow: ['fib-ped-stalk', 'fib-ped-1'],
        svgHide: ['fib-im-1', 'fib-im-2', 'fib-sm-1', 'fib-ss-1', 'fib-cerv-1']
      },
      cervical: {
        badge: '<span class="badge badge-red">FIGO Type 8</span>',
        title: 'Cervical / Special Fibroid',
        body: 'Fibroids within the cervical stroma, broad ligament, or parasitic fibroids (detached from uterus, obtaining blood supply from other pelvic structures). Rare but clinically important. FIGO Type 8 — "Other".',
        items: [
          'Urinary retention — cervical fibroid may compress urethra or bladder neck (high-yield exam scenario)',
          'Broad ligament fibroid — between peritoneal leaves; compresses ureter → hydronephrosis',
          'Parasitic fibroid — may attach to omentum, bowel; complex surgical excision required',
          'Difficult surgical access — cervical fibroid increases risk of ureteric injury during hysterectomy',
          'Management: highly individualised; often requires complex surgical planning; pre-op MRI essential'
        ],
        svgShow: ['fib-cerv-1'],
        svgHide: ['fib-im-1', 'fib-im-2', 'fib-sm-1', 'fib-ss-1', 'fib-ped-stalk', 'fib-ped-1']
      }
    };

    document.querySelectorAll('.type-tab').forEach(tab => {
      tab.addEventListener('click', () => {
        const type = tab.dataset.type;
        document.querySelectorAll('.type-tab').forEach(t => t.classList.remove('active'));
        tab.classList.add('active');
        const data = typeData[type];
        // Update SVG
        data.svgShow.forEach(id => { const el = document.getElementById(id); if (el) el.style.display = ''; });
        data.svgHide.forEach(id => { const el = document.getElementById(id); if (el) el.style.display = 'none'; });
        // Update detail panel
        document.getElementById('typeDetail').innerHTML = `
      <div class="detail-tag">${data.badge}</div>
      <div class="detail-title">${data.title}</div>
      <div class="detail-body">${data.body}</div>
      <ul class="detail-list">${data.items.map(i => `<li>${i}</li>`).join('')}</ul>
    `;
        gsap.fromTo('#typeDetail', { opacity: 0, y: 15 }, { opacity: 1, y: 0, duration: 0.4 });
      });
    });

    // ---- FIGO CARDS ----
    document.querySelectorAll('.figo-card').forEach(card => {
      card.addEventListener('click', () => {
        document.querySelectorAll('.figo-card').forEach(c => c.classList.remove('active'));
        card.classList.add('active');
      });
    });

    // ---- DX FLOW REVEAL ----
    document.querySelectorAll('.dx-step').forEach((step, i) => {
      ScrollTrigger.create({
        trigger: step,
        start: 'top 80%',
        once: true,
        onEnter: () => {
          gsap.to(step, {
            opacity: 1, x: 0, duration: 0.6,
            delay: i * 0.1, ease: 'power2.out',
            onStart: () => step.classList.add('revealed')
          });
        }
      });
    });

    // ---- DRUG CARD FLIP (touch support) ----
    document.querySelectorAll('.drug-card').forEach(card => {
      card.addEventListener('click', () => card.classList.toggle('flipped'));
      card.addEventListener('keydown', e => {
        if (e.key === 'Enter' || e.key === ' ') {
          e.preventDefault();
          card.classList.toggle('flipped');
        }
      });
    });

    // ---- EXAM PEARLS ACCORDION ----
    function togglePearl(header) {
      const item = header.closest('.pearl-item');
      const isOpen = item.classList.contains('open');
      // Close all
      document.querySelectorAll('.pearl-item.open').forEach(p => p.classList.remove('open'));
      if (!isOpen) item.classList.add('open');
    }

    // ---- QUIZ ----
    let currentQ = 0;
    let score = 0;
    let answered = [false, false, false, false, false];

    function answerQ(qIndex, optIndex, correct) {
      if (answered[qIndex]) return;
      answered[qIndex] = true;
      if (correct) score++;

      const qEl = document.getElementById(`q${qIndex}`);
      const options = qEl.querySelectorAll('.quiz-option');
      const exp = document.getElementById(`exp${qIndex}`);

      options.forEach((opt, i) => {
        opt.style.pointerEvents = 'none';
        const wasClicked = i === optIndex;
        if (wasClicked && correct) opt.classList.add('correct');
        else if (wasClicked && !correct) opt.classList.add('incorrect');
        else if (!wasClicked) {
          // Find correct option
          const correctOpt = qEl.querySelectorAll('.quiz-option')[
            Array.from(options).findIndex((_, ii) => {
              // Check by looking at onclick
              const onc = options[ii].getAttribute('onclick') || '';
              return onc.includes('true');
            })
          ];
        }
      });
      // Mark correct answer green
      options.forEach(opt => {
        const onc = opt.getAttribute('onclick') || '';
        if (onc.includes('true')) opt.classList.add('correct');
      });

      exp.classList.add('visible');

      // Update progress dot
      const dots = document.querySelectorAll('.quiz-progress-dot');
      dots[qIndex].classList.remove('active');
      dots[qIndex].classList.add('done');

      // Show next button or finish
      const nav = document.getElementById('quizNav');
      if (qIndex < 4) {
        nav.innerHTML = `<span></span><button class="btn btn-primary" onclick="nextQ(${qIndex})">Next Question →</button>`;
        if (qIndex + 1 < 5) dots[qIndex + 1].classList.add('active');
      } else {
        setTimeout(showScore, 1200);
      }
    }

    function nextQ(current) {
      document.getElementById(`q${current}`).style.display = 'none';
      document.getElementById(`q${current + 1}`).style.display = 'block';
      currentQ = current + 1;
      document.getElementById('quizNav').innerHTML = `<span style="font-size:0.8rem;color:var(--text-3);font-family:var(--font-mono);">select an answer to continue</span>`;
      gsap.fromTo(`#q${currentQ}`, { opacity: 0, y: 20 }, { opacity: 1, y: 0, duration: 0.5 });
    }

    function showScore() {
      document.getElementById('quizQuestions').style.display = 'none';
      document.getElementById('quizNav').style.display = 'none';
      const scoreEl = document.getElementById('quizScore');
      const numEl = document.getElementById('scoreNumber');
      const labelEl = document.getElementById('scoreLabel');
      numEl.textContent = `${score}/5`;
      if (score === 5) labelEl.textContent = 'Outstanding — Perfect score! You clearly know your fibroids.';
      else if (score >= 4) labelEl.textContent = 'Excellent — Minor gaps only. Review the incorrect answers.';
      else if (score >= 3) labelEl.textContent = 'Good foundation — Review pathophysiology, FIGO classification, and emergency management.';
      else labelEl.textContent = 'Keep studying — Focus on FIGO classification, key drug safety alerts, and clinical scenarios.';
      scoreEl.classList.add('visible');
      document.querySelectorAll('.quiz-progress-dot').forEach(d => { d.classList.remove('active'); d.classList.add('done'); });
    }

    function resetQuiz() {
      currentQ = 0; score = 0; answered = [false, false, false, false, false];
      for (let i = 0; i < 5; i++) {
        const qEl = document.getElementById(`q${i}`);
        qEl.style.display = i === 0 ? 'block' : 'none';
        qEl.querySelectorAll('.quiz-option').forEach(o => {
          o.classList.remove('correct', 'incorrect');
          o.style.pointerEvents = '';
        });
        document.getElementById(`exp${i}`).classList.remove('visible');
      }
      document.getElementById('quizScore').classList.remove('visible');
      document.getElementById('quizQuestions').style.display = 'block';
      document.getElementById('quizNav').style.display = 'flex';
      document.getElementById('quizNav').innerHTML = `<span style="font-size:0.8rem;color:var(--text-3);font-family:var(--font-mono);">select an answer to continue</span>`;
      const dots = document.querySelectorAll('.quiz-progress-dot');
      dots.forEach((d, i) => { d.classList.remove('done', 'active'); if (i === 0) d.classList.add('active'); });
    }

    // ---- KEYBOARD NAVIGATION ----
    let currentSectionIndex = 0;
    document.addEventListener('keydown', e => {
      if (e.key === 'ArrowDown' || e.key === 'ArrowRight') {
        e.preventDefault();
        currentSectionIndex = Math.min(currentSectionIndex + 1, sections.length - 1);
        gsap.to(window, { duration: 0.8, scrollTo: `#${sections[currentSectionIndex].id}`, ease: 'power2.inOut' });
      } else if (e.key === 'ArrowUp' || e.key === 'ArrowLeft') {
        e.preventDefault();
        currentSectionIndex = Math.max(currentSectionIndex - 1, 0);
        gsap.to(window, { duration: 0.8, scrollTo: `#${sections[currentSectionIndex].id}`, ease: 'power2.inOut' });
      } else if (e.key === 'f' || e.key === 'F') {
        if (!document.fullscreenElement) document.documentElement.requestFullscreen();
        else document.exitFullscreen();
      }
    });

    // Track current section for keyboard nav
    sections.forEach((s, i) => {
      ScrollTrigger.create({
        trigger: `#${s.id}`,
        start: 'top 60%',
        onEnter: () => { currentSectionIndex = i; },
        onEnterBack: () => { currentSectionIndex = i; }
      });
    });

    // ---- HIDE KBD HINT AFTER 5s ----
    setTimeout(() => {
      const hint = document.getElementById('kbd-hint');
      if (hint) hint.classList.add('hidden');
    }, 5000);
    window.addEventListener('scroll', () => {
      const hint = document.getElementById('kbd-hint');
      if (hint && !hint.classList.contains('hidden')) hint.classList.add('hidden');
    }, { once: true });

    // ---- PARALLAX HERO ORBS ----
    ScrollTrigger.create({
      trigger: '#hero',
      start: 'top top',
      end: 'bottom top',
      scrub: 1,
      onUpdate: (self) => {
        const orbs = document.querySelectorAll('#hero .orb');
        orbs.forEach((orb, i) => {
          const speed = [0.3, 0.5, 0.2][i] || 0.3;
          orb.style.transform = `translate(0, ${self.progress * 100 * speed}px) scale(1)`;
        });
      }
    });

    // ---- SLIDE COUNTER ----
    const slideCounter = document.getElementById('slide-counter');
    if (slideCounter) {
      sections.forEach((s, i) => {
        ScrollTrigger.create({
          trigger: `#${s.id}`,
          start: 'top 50%',
          onEnter: () => { slideCounter.textContent = `${i + 1} / ${sections.length}`; },
          onEnterBack: () => { slideCounter.textContent = `${i + 1} / ${sections.length}`; }
        });
      });
    }

    // ---- DRUG CARD SHOW ALL TOGGLE ----
    let drugsExpanded = false;
    window.toggleAllDrugCards = function () {
      drugsExpanded = !drugsExpanded;
      const cards = document.querySelectorAll('.drug-card-inner');
      const btn = document.getElementById('showAllDrugs');
      cards.forEach(card => {
        if (drugsExpanded) {
          card.style.transform = 'rotateY(180deg)';
        } else {
          card.style.transform = '';
        }
      });
      btn.textContent = drugsExpanded ? 'Hide Details' : 'Show All Details';
    };
  </script>
</body>

</html>